https://rjrindex.com/articles/quantitative-radiomics-based-biomarker-discovery-for-prognostic-stratification-in-gastroesophageal-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-characterization-of-resectable-pancreatic-ductal-adenocarcinoma-r-pdac-on-the-neopancone-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preliminary-results-of-tumor-informed-minimal-residual-disease-detection-in-pancreatic-cancer-patien 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-postoperative-ctdna-dynamics-on-eligibility-for-the-altair-randomized-trial-in-patients-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-clinical-and-molecular-comparative-analysis-of-kras-exon-2-and-kras-non-exon-2-mutated-colorectal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-rw-outcomes-of-durvalumab-plus-gemcitabine-and-cisplatin-d-gemcis-or-gemcis-in-pati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-nutrition-in-patients-with-pancreatic-cancer-nuance-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-for-phase-ii-study-of-durvalumab-d-and-tremelimumab-t-plus-pet-directed-chemor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/utility-of-pancreatic-cancer-screening-and-detection-in-patients-with-pathogenic-germline-variants 2026-08-24 monthly 0.7 https://rjrindex.com/articles/do-glucagon-like-peptide-1-receptor-agonists-offer-protective-effect-on-colon-cancer-risk 2026-08-24 monthly 0.7 https://rjrindex.com/articles/colorectal-organ-preservation-in-lynch-syndrome-a-tailored-conservative-surgical-approach 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multicenter-retrospective-study-on-treatment-outcomes-of-gastric-cancer-with-positive-peritoneal-cyt 2026-08-24 monthly 0.7 https://rjrindex.com/articles/once-daily-oral-paltusotine-in-the-treatment-of-patients-with-carcinoid-syndrome-biomarker-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1-first-in-human-open-label-study-evaluating-the-safety-tolerability-pharmacokinetics-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-23-randomized-study-of-bms-986504-with-nab-paclitaxel-nab-p-and-gemcitabine-gem-in-firs 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cost-utility-of-geriatric-assessment-and-management-in-older-adults-with-cancer-model-based-economi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/feasibility-safety-and-efficacy-of-endoscopic-ultrasound-guided-alpha-radiotherapy-for-advanced-pan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/targeting-chemoresistance-a-phase-ii-study-of-iadademstat-iada-with-paclitaxel-p-in-extrapulmon 2026-08-24 monthly 0.7 https://rjrindex.com/articles/investigating-disparities-in-hepatocellular-carcinoma-and-their-effect-on-patterns-of-systemic-care 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-gastric-cancer-recurrence-after-endoscopic-submucosal-dissection 2026-08-24 monthly 0.7 https://rjrindex.com/articles/alternating-neoadjuvant-gemcitabine-nab-paclitaxel-gnp-and-nal-irinotecan-5-fluorouracil-and-foli 2026-08-24 monthly 0.7 https://rjrindex.com/articles/examining-the-link-between-tobacco-use-and-gastric-cancer-mortality-a-us-population-based-perspec 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-chemotherapy-in-resectable-gastric-cancer-an-international-propensity-matched-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/locoregional-therapy-for-hepatocellular-carcinoma-before-transplant-impact-on-tumor-necrosis-tumor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-study-to-investigate-the-efficacy-and-safety-of-acoustic-cluster-therapy-with-modified-fol 2026-08-24 monthly 0.7 https://rjrindex.com/articles/design-of-a-hybrid-site-and-decentralized-clinical-research-study-of-an-early-detection-blood-test-f 2026-08-24 monthly 0.7 https://rjrindex.com/articles/antibody-mediated-blockade-of-gremlin-1-in-combination-with-gemcitabine-or-mek-inhibition-in-a-genet 2026-08-24 monthly 0.7 https://rjrindex.com/articles/physical-activity-and-molecular-residual-disease-mrd-in-stage-iii-colon-cancer-findings-from-calg 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-of-a-vaginal-dilator-during-chemoradiation-for-anal-cancer-to-mitigate-toxicity 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-benefit-of-nutritional-support-in-advanced-gastric-cancer-patients-receiving-chemotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-line-chemotherapy-in-metastatic-colorectal-cancer-comparative-outcomes-from-a-resource-limite 2026-08-24 monthly 0.7 https://rjrindex.com/articles/t-core2401-trial-a-randomized-phase-ii-trial-of-mfolfox6-plus-cetuximab-versus-mfolfox6-plus-bevaci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pooled-analysis-of-individual-patient-data-ipd-from-clinical-trials-of-trifluridinetipiracil-ftd 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-real-world-comparison-of-overall-survival-os-in-deficient-mismatch-repairmicrosatellite-instabi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/proposal-of-a-novel-pnd-based-staging-system-for-locoregional-gastric-neuroendocrine-carcinoma-a-mu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/diagnostic-accuracy-of-circulating-tumor-dna-for-early-detection-of-colorectal-cancer-a-systematic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/biomarker-driven-and-evidence-based-therapy-for-metastatic-colorectal-cancer-beat-crc-a-system-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-in-human-study-of-an-implantable-microdevice-for-personalized-drug-testing-in-colorectal-liver 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nivolumab-plus-chemotherapy-in-her2-negative-metastatic-gastric-gej-and-esophageal-adenocarcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-expanding-utility-of-diagnostic-laparoscopy-in-pancreatic-ductal-adenocarcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/legal-guidance-and-advocacy-for-caregivers-legacy-care-a-pilot-clinical-trial-for-patients-with-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/wnt-pathway-alterations-in-bevacizumab-treated-early-onset-colorectal-cancer-an-artificial-intellig 2026-08-24 monthly 0.7 https://rjrindex.com/articles/artemide-gastric01-a-phase-3-randomized-study-of-rilvegostomig-with-fluoropyrimidine-and-trastuzuma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/chemotherapy-for-locally-advanced-pancreatic-cancer-the-dilemma-of-david-versus-goliath-after-neopa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ierbb3i-driver-genomic-alterations-in-intrahepatic-cholangiocarcinoma-a-ge 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inferring-optimal-detection-of-imtapi-homozygous-loss-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/role-of-liquid-biopsy-in-diagnosis-prognosis-and-monitoring-of-hepatocellular-carcinoma-a-systema 2026-08-24 monthly 0.7 https://rjrindex.com/articles/validation-of-cancatch-surf-assay-for-tissue-agnostic-detection-of-minimal-residual-disease-in-color 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-of-locally-advanced-mismatch-repair-deficient-colorectal-tumours-treated-with-im 2026-08-24 monthly 0.7 https://rjrindex.com/articles/artificial-intelligence-approach-to-estimating-trial-feasibility-with-oncollm 2026-08-24 monthly 0.7 https://rjrindex.com/articles/quantifying-mlh1-promoter-methylation-via-liquid-biopsy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-single-center-prospective-study-to-evaluate-effectiveness-of-68ga-fapi-petct-in-the-initial-evalu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-real-world-study-of-claudin-182-cldn182-association-with-molecular-subtypes-mutationsbiomark 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-predictors-and-evolutionary-correlates-of-chemotherapy-response-in-pancreatic-ductal-adenoca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multicenter-nonrandomized-clinical-trial-to-evaluate-the-efficacy-and-toxicity-of-a-combination-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimising-outcomes-in-young-onset-metastatic-colorectal-cancer-from-a-multidisciplinary-model-of-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-recurrence-patterns-in-rectal-cancer-after-neoadjuvant-therapy-insights-from-25-years-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessment-of-the-impact-of-proton-pump-inhibitor-ppi-exposure-on-survival-outcomes-in-patients-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparative-analysis-of-immunotherapy-based-combination-in-first-line-management-of-hepatocellular-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/utility-of-circulating-tumor-dna-in-patients-with-resectable-pancreatic-cancer-using-a-patient-speci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-and-economic-outcomes-of-robotic-vs-open-gastrectomy-a-propensity-score-matched-analysis-d 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-multicenter-randomized-phase-2-study-evaluating-the-efficacy-and-safety-of-hlx43-an-anti-pd-l1-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multiomic-profiling-to-identify-pharmacodynamic-and-response-biomarkers-for-casdozokitug-with-pd-l1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-treatment-patterns-and-outcomes-in-metastatic-squamous-cell-carcinoma-of-the-anal-canal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinicopathologic-features-and-overall-survival-of-patients-with-early-onset-colorectal-cancer-in-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-study-of-pembrolizumab-plus-chemotherapy-with-short-course-radiotherapy-as-induction-trea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-characteristics-clinical-profiling-and-outcomes-of-advanced-pancreatic-ductal-adenocarcino 2026-08-24 monthly 0.7 https://rjrindex.com/articles/longitudinal-clinical-validation-of-the-northstar-response-using-methylated-ctdna-as-a-dynamic-treat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/relative-survival-at-1-3-5-and-10-years-by-raceethnicity-in-colorectal-cancer-a-seer-based-anal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-primary-results-of-a-randomized-phase-ii-trial-of-trifluridinetipiracil-ftdtpi-plus-ramuciru 2026-08-24 monthly 0.7 https://rjrindex.com/articles/proactif-final-results-from-the-largest-prospective-real-world-study-of-1196-primary-liver-cancer-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-prospective-comparison-of-sorafenib-and-lenvatinib-as-first-line-therapy-for-unresectable 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-carcinoid-syndrome-in-small-versus-large-intestinal-neuroendocrine-tumors 2026-08-24 monthly 0.7 https://rjrindex.com/articles/key-lessons-from-phase-i-trials-in-gastroesophageal-cancer-treated-in-gustave-roussy-cancer-center 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-determinants-of-survival-and-a-predictive-immune-biomarker-for-immunotherapy-in-fibrolamell 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-pralsetinib-in-ireti-fusion-posi-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-peritoneal-immune-landscape-in-gastrointestinal-peritoneal-metastasis-patients-and-the-impact-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trifluridine-tipiracil-versus-radioembolization-for-patients-with-refractory-colorectal-liver-metast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clonal-hematopoiesis-of-indeterminate-potential-a-potential-risk-factor-for-gi-malignancies-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-and-prognostic-factors-for-immune-checkpoint-inhibitors-in-dmmrmsi-h-metastatic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/international-and-contrasting-perspectives-on-early-onset-colorectal-cancer-awareness-testing-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/open-versus-minimally-invasive-surgery-for-large-type-3-and-type-4-gastric-cancer-a-multicenter-ret 2026-08-24 monthly 0.7 https://rjrindex.com/articles/primary-squamous-cell-carcinoma-of-the-small-intestine-a-population-based-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-multicenter-phase-ii-trial-of-ramucirumab-plus-irinotecan-in-patients-with-early-relapsed-gastric 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-universal-germline-sequencing-in-white-vs-minority-populations-with-primary-gastroint 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-randomized-study-of-atezolizumab-plus-multikinase-inhibitor-mki-versus-mki-alone-in-pat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sglt2-inhibitors-and-outcomes-in-pancreatic-cancer-a-large-scale-propensity-matched-cohort-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-and-immune-contexture-in-smarca4-deficient-gastric-cancer-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tumor-informed-ctdna-monitoring-during-surveillance-for-early-detection-of-recurrence-in-patients-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-study-of-tinengotinib-in-advanced-cholangiocarcinoma-analysis-of-molecular-response-and-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/geographic-distribution-and-equity-in-access-to-gastrointestinal-cancer-clinical-trials-in-the-unite 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-liposomal-irinotecan-in-patients-with-advanced-pancreatic-cancer-a-prospecti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-results-of-the-phase-12-study-of-tsn1611-a-highly-selective-kras-g12d-inhibitor-in-patien 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preoperative-nalirifox-versus-upfront-surgery-in-high-risk-resectable-pancreatic-cancer-a-randomize 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-efficacy-and-safety-of-surufatinib-in-advanced-neuroendocrine-neoplasm 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-i-trial-of-high-dose-sbrt-combined-with-atezolizumab-and-bevacizumab-in-advanced-hepatocellula 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-study-of-stereotactic-body-radiotherapy-and-focal-adhesion-kinase-inhibitor-in-advanced-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-impact-of-chemotherapy-and-immune-checkpoint-inhibitor-treatment-in-high-risk-stage-ii-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/gut-microbiota-perturbations-in-response-to-sars-cov-2-and-survival-outcomes-in-patients-with-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-simple-abc-score-for-prognosis-stratification-and-treatment-selection-in-advanced-hepatocellular-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/external-validation-of-magic-d-in-taiwanese-patients-with-advanced-biliary-tract-cancer-receiving-du 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-3-randomized-double-blind-placebo-controlled-study-of-lecithinized-superoxide-dismutase 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immunomodulatory-effects-of-lenvatinib-targeting-immunosuppressive-macrophages-in-combination-with-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-relationship-between-the-diagnostic-interval-length-and-survival-in-colon-cancer-the-role-of-di 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-study-of-combined-therapy-folfox-with-dabrafenib-and-cetuximabpanitumumab-as-first-line-tre 2026-08-24 monthly 0.7 https://rjrindex.com/articles/gemini-perioperative-periop-gastric-a-phase-2-study-of-novel-agent-based-combinations-as-periop-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/disparities-in-pancreatic-cancer-burden-across-states-sex-and-risk-factors-a-gbd-2021-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-pilot-study-of-atrovastatin-aspirin-asa-chemoprevention-in-patients-pts-with-lynch-syndrom 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-patterns-in-advanced-gastric-cancer-gc-across-racial-and-ethnic-groups-in-the-immunother 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-anti-egfr-therapy-in-elderly-mcrc-patients-a-monocentric-analysis-stratified-by-comorbid 2026-08-24 monthly 0.7 https://rjrindex.com/articles/incidental-gastric-micro-gists-in-sleeve-gastrectomy-incidence-and-intraoperative-management-in-a-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/biomarker-prevalence-in-us-patients-with-gastricgastroesophageal-junction-adenocarcinoma-gea-from 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinicopathological-and-mutational-factors-related-to-survival-in-patients-with-gastrointestinal-str 2026-08-24 monthly 0.7 https://rjrindex.com/articles/plasma-gpc3-and-its-association-with-tumor-gpc3-expression-and-clinical-outcomes-in-advanced-hepatoc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-sarcomatoid-hepatocellular-carcinoma-patients-treated-with-immunotherapy-a-multi-instit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-glucagon-like-peptide-1-receptor-agonists-on-clinical-outcomes-in-pancreatic-cancer-a-lar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-outcomes-with-tremelimumab-t-rechallenge-in-the-phase-3-himalaya-study-of-t-plus-durvalumab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-outcomes-of-patients-with-m-iidh1i-cholangioc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preliminary-phase-1-results-of-incb161734-a-novel-oral-kirsten-rat-sarcoma-kras-g12d-inhibitor-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-triweekly-cetuximab-in-combination-with-capecitabine-as-first-line-maintenanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effects-of-soy-food-consumption-in-preventing-hepatocellular-carcinoma-a-systematic-review-and-meta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/triunite-02-a-phase-2-open-label-randomized-study-of-neoadjuvant-capeox-plus-tislelizumab-and-chi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racial-and-ethnic-differences-in-pancreatic-cancer-survival-and-treatment-at-a-high-volume-center 2026-08-24 monthly 0.7 https://rjrindex.com/articles/online-patient-and-caregiver-conversations-focused-on-neuroendocrine-neoplasms-nens-a-global-them 2026-08-24 monthly 0.7 https://rjrindex.com/articles/narmafotinib-amp945-in-combination-with-gemcitabine-and-nab-paclitaxel-as-first-line-treatment-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/arb1002-a-potential-first-in-class-cdh17-specific-adc-for-treatment-of-pancreatic-and-other-gastro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-and-toxicity-of-stereotactic-mr-guided-adaptive-radiation-therapy-smart-in-local 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-chemotherapy-plus-pd-1-inhibitor-with-chemoradiotherapy-for-metastatic-escc-patients-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-durvalumab-plus-gemcitabinecisplatin-in-combined-hepatocellular-cholangiocar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/estimating-the-clinical-and-economic-impact-of-delaying-recurrence-in-resectable-gastric-and-gastroe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multicenter-prospective-validation-of-panclaudinai-an-ai-for-predicting-claudin-182-from-ct-in-pan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparative-genomic-profiles-of-ierbb2her2i-mutant-an 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-palliative-care-and-acute-care-use-at-the-end-of-life-in-young-adults-with-gi-cancers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/small-cell-carcinoma-and-large-cell-neuroendocrine-carcinoma-of-colon-and-rectum-incidence-surviva 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-iib-study-of-inavolisib-inavo-bevacizumab-bev-or-cetuximab-cetux-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/differential-efficacy-of-immunotherapy-in-hepatocellular-carcinoma-hcc-based-on-etiology-a-system 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparative-outcomes-of-evolving-vs-conventional-regimens-in-braf-v600e-mutated-metastatic-colorecta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adebrelimab-combined-with-albumin-paclitaxel-and-nedaplatin-as-neoadjuvant-therapy-for-locally-advan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-vs-late-onset-primary-colon-adenocarcinoma-gene-expression-dependent-overall-survival-in-chem 2026-08-24 monthly 0.7 https://rjrindex.com/articles/postoperative-complications-and-overall-survival-in-elderly-patients-with-gastric-cancer-a-retrospe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1b2-multicenter-open-label-study-to-evaluate-the-efficacy-and-safety-of-gsk5764227-gsk2 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reducing-the-resection-range-after-neoadjuvant-therapy-for-locally-advanced-upper-rectal-and-rectosi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-epacadostat-incb024360-combined-with-short-course-radiotherapy-in-patients-with-locall 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-me 2026-08-24 monthly 0.7 https://rjrindex.com/articles/predictive-value-of-cldn182-supsup-cd8 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-of-resected-gastrointestinal-stromal-tumors-treated-with-3-years-of-adjuvant-imati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-study-of-durvalumab-plus-olaparib-in-patients-with-metastatic-pancreatic-cancer-and-dna-dam 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-chemotherapy-and-serplulimab-in-msspmmr-locally-advanced-rectal-cancer-firm-a-phase 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-evaluation-of-zinc-clobetasol-and-combination-prophylaxis-for-regorafenib-induced-hand 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-factors-associated-with-advanced-colorectal-neoplasia-in-average-risk-asymptomatic-individ 2026-08-24 monthly 0.7 https://rjrindex.com/articles/meteorite-a-phase-ii-study-of-y-90-capecitabine-and-atezolizumab-in-oligometastatic-crc-bruog430 2026-08-24 monthly 0.7 https://rjrindex.com/articles/shared-genetic-susceptibility-between-autoimmune-diseases-and-pancreatic-ductal-adenocarcinoma-a-pa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-effectiveness-and-safety-of-apixaban-versus-rivaroxaban-in-pancreatic-cancer-associated-v 2026-08-24 monthly 0.7 https://rjrindex.com/articles/utilization-of-immunotherapy-as-a-neoadjuvant-treatment-in-liver-transplant-recipients-with-hepatobi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-pathological-and-molecular-characteristics-of-advanced-colorectal-cancer-in-younger-vs-ol 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racial-differences-in-the-impact-of-pre-existing-mental-health-diagnosis-on-colorectal-cancer-surviv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-value-of-ctdna-monitoring-in-patients-with-resectable-pancreatic-ductal-adenocarcinoma-du 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prevalence-and-clinical-profile-of-inflammatory-bowel-disease-patients-with-small-bowel-cancer-a-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/btn1a1-expression-as-a-biomarker-for-patient-selection-phase-1b-ihc-analysis-and-clinical-outcomes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-longitudinal-comprehensive-distress-screening-on-cancer-related-distress-and-overall-survi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-ca19-9-reduction-on-resectability-and-survival-in-pancreatic-cancer-patients-following-neo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patient-characteristics-first-line-treatments-and-overall-survival-among-locally-advanced-unresec 2026-08-24 monthly 0.7 https://rjrindex.com/articles/stereotactic-body-radiotherapy-for-resectable-pancreatic-ductal-adenocarcinoma-in-patients-unfit-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/concordance-of-programmed-death-ligand-1-pd-l1-status-in-primary-esophageal-squamous-cell-carcinom 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-liver-cancer-and-frailty-in-elderly-life-study-understanding-longitudinal-functional-status-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-symptom-patterns-among-young-medicaid-insured-individuals-with-colorectal-cancer-a-population 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-efficacy-and-safety-of-third-line-regorafenib-versus-fruquintinib-in-the-treatment-of-metastatic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ib-trial-on-the-safety-and-feasibility-of-low-dose-radiotherapy-combined-with-immunochemothe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-molecular-profile-and-treatment-patterns-in-advanced-gastroesophageal-adenocarcinoma-a-b 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-quizartinib-for-newly-diagnosed-iflt3i-intern 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-ilustro-trial-of-1l-zolbetuximab-plus-mfolfox6-and-nivolumab-in-patients-with-cldn182-loca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/breakwater-primary-analysis-of-first-line-1l-encorafenib-cetuximab-ec-folfiri-in-braf-v600e 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-outcomes-of-the-plato-act5-randomised-trial-personalizing-anal-cancer-radiotherapy-dose 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-asp3082-monotherapy-or-in-combination-with-mfolfirinox-in-patients-pts-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/investigating-clinical-and-molecular-characteristics-of-patients-with-pik3ca-mutation-with-and-witho 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-study-of-cabozantinib-cabo-combined-with-ipilimumab-ipinivolumab-nivo-and-transarteri 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-randomized-study-of-telisotuzumab-adizutecan-abbv-400-temab-a-in-combination-with-stand 2026-08-24 monthly 0.7 https://rjrindex.com/articles/machine-learning-based-detection-of-multiple-cancers-using-5-hydroxymethylcytosine-at-cancer-mutatio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-efficacy-of-celiac-plexus-radiosurgery-for-pancreatic-cancer-pain-an-international-phase 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bevacizumab-atezolizumab-b-a-durvalumab-tremelimumab-d-t-and-lenvatinib-l-in-advanced-hepatoc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-infusion-timing-it-on-survival-outcomes-across-gastrointestinal-gi-malignancies-a-mul 2026-08-24 monthly 0.7 https://rjrindex.com/articles/examining-the-role-of-circulating-tumor-dna-in-gastroesophageal-cancers-treated-with-curative-intent 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparative-safety-profiles-of-atezolizumab-bevacizumab-vs-tyrosine-kinase-inhibitors-in-advanced-he 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterization-of-dpyd-alterations-and-treatment-related-toxicity-in-a-chilean-cohort-of-cancer-pa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/leveraging-early-onset-adverse-events-aes-to-inform-treatment-strategies-in-pan-gastrointestinal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/type-2-diabetes-and-the-risk-of-gastrointestinal-cancers-in-individuals-with-metabolic-dysfunction-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/three-year-and-five-year-outcomes-of-a-phase-ii-study-of-perioperative-capeox-therapy-for-advanced-g 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-novel-tyrosine-kinase-inhibitors-in-rare-gist-subtypes-a-clinico-genomic-analysis-from 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-cohort-study-of-concurrent-chemoradiotherapy-combined-with-or-without-immune-checkpoint-inhibitor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/everolimus-or-lanreotide-who-is-the-true-winner-for-gi-nets 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hepatocellular-carcinoma-second-line-systemic-therapies 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-interplay-of-hla-diversity-and-copy-loss-t-cell-profiles-and-immunotherapy-efficacy-in-colorec 2026-08-24 monthly 0.7 https://rjrindex.com/articles/altopanc-local-ablative-therapies-in-oligometastatic-pancreatic-adenocarcinoma-a-bi-national-french 2026-08-24 monthly 0.7 https://rjrindex.com/articles/critics-ii-a-multicenter-randomized-phase-ii-trial-of-neo-adjuvant-chemotherapy-followed-by-surgery 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tislelizumab-tisle-combined-with-pofi-irinotecan-paclitaxel-oxaliplatin-and-5-fulevoleucovori-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/liposomal-irinotecan-carboplatin-or-oxaliplatin-lyricx-with-or-without-nivolumab-in-the-first-lin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-of-durvalumab-or-pembrolizumab-plus-gemcitabine-and-cisplatin-gemcis-in-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-zolbetuximab-plus-chemotherapy-for-cldn182-positive-gastric-cancer-a-single 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-comparative-analysis-of-colorectal-cancer-in-high-income-north-america-vs-asian-subregions-tempor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mapping-preventable-risks-obesity-alcohol-and-hepatocellular-carcinoma-in-the-us 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-patterns-and-survival-outcomes-in-klatskin-tumors-a-real-world-analysis-of-the-trinetx-ne 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preclinical-rationale-for-fgfr1-blockade-in-colorectal-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-of-transcriptomic-signatures-of-irad51i-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effect-of-surgeon-specialty-and-health-system-characteristics-on-outcomes-after-pancreatic-adenocarc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/non-invasive-early-detection-of-gastric-cancer-using-red-blood-cell-dna-genomic-signature-a-multi-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-efficacy-of-avapritinib-for-unresectable-or-metastatic-gastrointestinal-stromal-tumors-with-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mtap-deficient-pancreatic-adenocarcinoma-clinical-and-molecular-features 2026-08-24 monthly 0.7 https://rjrindex.com/articles/factors-affecting-overall-survival-in-early-onset-gastroenteropancreatic-neuroendocrine-tumours-gep 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bridging-gaps-in-colorectal-cancer-care-real-world-impact-of-a-national-clinical-navigation-program 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-hepatic-arterial-infusion-chemotherapy-with-folfox-or-folfiri-plus-drug-eluti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reevaluating-complete-response-assessing-whether-imaging-alone-is-sufficient-to-predict-survival-af 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-cost-of-care-how-insurance-status-and-socioeconomic-factors-affect-colorectal-cancer-outcomes-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-following-stereotactic-mr-guided-adaptive-radiation-therapy-smart-in-medically-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/liver-transplantation-for-unresectable-colorectal-liver-metastases-pooled-real-world-data-from-all 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-i-trial-of-emavusertib-ca-4948-in-combination-with-folfoxpd-1-inhibitor-trastuzumab-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-neoadjuvant-short-course-radiotherapy-followed-by-ivonescimab-with-or-without-chem 2026-08-24 monthly 0.7 https://rjrindex.com/articles/amivantamab-plus-folfox-or-folfiri-in-irasbrafi-wild-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterization-of-lat1-related-gene-expression-and-its-impact-on-prognostic-tumor-mutations-and-ga 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-tumor-dna-profiling-and-its-association-with-clinical-outcomes-in-metastatic-colorectal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-patient-reported-outcomes-in-stage-iiiii-rectal-cancer-in-the-netherlands 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-prospective-single-arm-phase-ii-study-of-trilaciclib-combined-with-immunotherapy-and-chemotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/decreasing-hypoxia-with-mitochondrial-inhibition-in-locally-advanced-rectal-cancer-phase-1-trial-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-and-sociodemographic-characterization-of-gastrointestinal-cancers-in-rural-patients-particip 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparative-efficacy-and-safety-of-durvalumab-and-pembrolizumab-combined-with-chemotherapy-in-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nivolumab-plus-ipilimumab-ni-in-patients-pts-with-colorectal-cancer-crc-with-brca12-alterati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pilot-study-of-stomach-cancer-early-detection-and-prevention-with-endoscopy-pilot-screen-acceptab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adverse-events-with-pd-1-inhibitors-in-gastric-cancer-a-real-world-comparative-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ibii-study-of-zanzalintinib-xl092-in-second-line-and-beyond-for-the-treatment-of-advanced 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-study-of-re-introduction-of-gemcitabine-plus-cisplatin-in-combination-with-durvalumab-aft 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-landscape-and-clinical-outcomes-of-mdm2-amplifications-in-biliary-tract-cancers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/emb-01-a-tetravalent-anti-egfrcmet-bispecific-antibody-in-the-left-sided-rasbraf-wild-type-lat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-significance-of-oligometastatic-esophageal-squamous-cell-carcinoma-a-retrospective-cohort 2026-08-24 monthly 0.7 https://rjrindex.com/articles/using-quantitative-pathologic-analysis-to-identify-microsatellite-stability-in-digitized-colorectal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prediction-of-chemotherapy-induced-peripheral-neuropathy-using-metadata-with-machine-learning-models 2026-08-24 monthly 0.7 https://rjrindex.com/articles/an-open-label-phase-2-study-of-total-neoadjuvant-therapy-tnt-consisting-of-flot-with-pembrolizumab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/transarterial-chemoembolization-tace-combined-with-sintilimab-and-bevacizumab-versus-tace-alone-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-1-dose-escalation-and-expansion-study-of-trop2-car-engineered-il-15-transduced-cord-blood-deri 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-patterns-and-outcomes-in-patients-diagnosed-with-metastatic-pancreatic-ductal-adenocarcino 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-early-c-reactive-protein-kinetics-as-an-early-response-marker-in-biliary-tract-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-1-study-of-lb1908-an-autologous-claudin-182-targeted-car-t-cell-product-in-subjects-with-ad 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-lirafugratinib-in-ifgfrii-naive 2026-08-24 monthly 0.7 https://rjrindex.com/articles/identification-of-pleiotropic-genetic-risk-variants-for-pancreatic-cancer-and-diabetes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/definitive-sbrt-in-unresectable-pancreatic-cancer-long-term-outcomes-with-moderate-vs-high-dose-app 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-novel-framework-to-grade-the-quality-of-surrogate-endpoints-at-the-trial-level-an-analysis-of-sur 2026-08-24 monthly 0.7 https://rjrindex.com/articles/care-delivery-among-patients-with-early-onset-versus-average-onset-cholangiocarcinoma-a-nationwide 2026-08-24 monthly 0.7 https://rjrindex.com/articles/obesity-associated-colorectal-cancer-and-the-association-with-chemokine-signaling-and-tumor-remodeli 2026-08-24 monthly 0.7 https://rjrindex.com/articles/young-onset-colorectal-cancer-yocrc-in-the-nationwide-precision-oncology-trial-impress-norway 2026-08-24 monthly 0.7 https://rjrindex.com/articles/coupling-tumor-genomics-whole-transcriptome-sequencing-and-patient-outcomes-to-define-the-tumor-mi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-trastuzumab-deruxtecan-in-her2-positive-advanced-gastric-and-gastroesophageal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-benefit-and-toxicity-of-combining-immunotherapy-with-gemcitabine-cisplatin-versus-standard 2026-08-24 monthly 0.7 https://rjrindex.com/articles/managing-the-primary-tumor-in-patients-with-rectal-cancer-and-synchronous-liver-metastases-the-role 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-factors-for-rapid-progression-in-metastatic-pancreatic-adenocarcinoma-clinical-histopat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hepatocellular-carcinoma-in-nevada-impact-of-hbvhcv-metabolic-syndrome-and-alcohol-use-disorder 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinicopathologic-features-treatment-patterns-and-outcomes-of-microsatellite-instability-high-msi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/molecular-characterization-of-resected-non-metastatic-pancreatic-cancer-pc-based-on 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multiomic-analysis-and-oncologic-outcomes-in-pancreatic-cancer-by-pin1-expression 2026-08-24 monthly 0.7 https://rjrindex.com/articles/investigating-the-association-of-inflammatory-markers-with-clinical-outcomes-of-patients-with-kras-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-line-immunotherapy-plus-gemcitabine-cisplatin-versus-chemotherapy-alone-in-advanced-cholangioc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-study-of-neoadjuvant-chemotherapy-with-fluorouracil-leucovorin-oxaliplatin-and-docetaxel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/improvement-of-survival-in-advanced-gastric-cancer-over-15-years-real-world-analysis-by-5-year-peri 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-anti-pd-l1-therapy-in-advanced-hepatocellular-carcinoma-with-or-without-metabolic-synd 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-in-locoregional-colorectal-cancer-incidence-by-race-and-ethnicity-in-us-adults-aged-45-49-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-of-a-prognostic-nomogram-to-guide-clinical-decision-making-in-metastatic-gastric-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/brain-metastases-in-gastro-esophageal-cancers-survival-and-prognostic-insights-from-an-asian-cohort 2026-08-24 monthly 0.7 https://rjrindex.com/articles/second-line-irinotecan-followed-by-third-line-cetuximab-plus-irinotecan-versus-second-line-cetuximab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/disparities-in-stage-iii-iv-squamous-cell-anal-carcinoma-scac-real-world-treatment-patterns-outc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-treatment-patterns-and-biomarker-testing-landscape-of-locally-advanced-gastricgastroesop 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-open-label-study-of-enfortumab-vedotin-in-patients-with-previously-treated-locally-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/monthly-alternating-nalirifox-and-gnp-for-metastatic-pancreatic-ductal-adenocarcinoma-altcap 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neuroligin-family-genes-expression-associated-with-first-line-treatment-outcomes-in-patients-pts-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-gastric-cancer-genome-explorer-a-spatial-and-single-cellular-registry-for-identifying-novel-cel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-neoadjuvant-her-2-targeted-therapy-in-resectable-her-2-positive-gastric-and-esophagogast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hospital-frailty-risk-score-and-in-hospital-mortality-after-pancreatectomy-in-adults-65-a-national 2026-08-24 monthly 0.7 https://rjrindex.com/articles/emerging-landscape-of-car-t-cell-therapy-in-gastrointestinal-malignancies-a-systematic-review-of-cl 2026-08-24 monthly 0.7 https://rjrindex.com/articles/oncologists-perceptions-of-evidence-and-standardization-in-appendiceal-cancer-management-a-nationa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/single-cell-sequencing-to-reveal-immune-features-of-treatment-response-to-neoadjuvant-chemoradiother 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ibii-study-of-fruquintinib-combined-with-sox-and-toripalimab-in-advanced-metastatic-gastricg 2026-08-24 monthly 0.7 https://rjrindex.com/articles/atezolizumab-plus-tiragolumab-in-combination-with-chemoradiotherapy-in-localized-squamous-cell-carci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cldn182-ihc-cutoff-and-efficacy-of-anti-cldn182-therapy-in-gastric-and-gastroesophageal-junction-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clonal-hematopoiesis-in-gi-cancer-frequent-but-not-a-predictor-of-oxaliplatin-neuropathy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-adebrelimab-plus-sox-and-nab-paclitaxel-in-resectable-locally-advanced-gastric-and-gastr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/total-neoadjuvant-treatment-in-locally-advanced-rectal-cancer-a-retrospective-multicentre-cohort-an 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-significance-of-serum-ca125-kinetics-as-an-early-predictor-of-tumor-progression-in-pancreat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-pilot-study-of-mobile-application-based-exercise-and-nutrition-interventions-for-gastrointestinal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/opportunities-for-harmonization-of-us-food-and-drug-administration-regulatory-decisions-exemplified 2026-08-24 monthly 0.7 https://rjrindex.com/articles/longitudinal-study-on-the-influence-of-physical-activity-in-managing-cancer-related-fatigue-in-patie 2026-08-24 monthly 0.7 https://rjrindex.com/articles/aspirin-use-and-pi3k-mutations-in-metastatic-colorectal-cancer-mcrc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/folfirinox-for-locally-advanced-pancreatic-cancer-the-need-for-individualized-strategies 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prevalence-of-clonal-hematopoiesis-of-indeterminate-potential-across-different-systemic-cancer-thera 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-ii-trial-evaluating-the-efficacy-of-zolbetuximab-in-the-second-line-for-claudin182 2026-08-24 monthly 0.7 https://rjrindex.com/articles/landmark-analysis-of-overall-survival-os-by-objective-response-in-patients-pts-with-previously-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/short-term-outcomes-of-induction-flot-plus-nivolumab-for-unresectable-locally-advanced-esophageal-sq 2026-08-24 monthly 0.7 https://rjrindex.com/articles/low-dose-radiotherapy-followed-by-chemoimmunotherapy-in-neoadjuvant-treatment-of-locally-advanced-es 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-comparing-the-use-of-glp-1-agonists-in-patients-with-hepatocellular-cancer-hcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparative-outcomes-of-apixaban-and-rivaroxaban-in-colon-cancer-patients-with-venous-thromboembolis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-in-advanced-gastric-cancer-among-elderly-patients-80-years-old-treated-with-che 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-indicators-in-lynch-syndrome-associated-stage-iv-colorectal-cancer-treated-with-pembroliz 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-randomized-double-blinded-international-phase-iii-trial-comparing-hlx22-in-combination-with-tras 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-regorafenib-in-patients-with-advanced-biliary-tract-cancer-an-updated-systematic-review 2026-08-24 monthly 0.7 https://rjrindex.com/articles/extracellular-vesicle-tissue-factor-and-venous-thromboembolism-outcomes-in-pancreatic-cancer-patient 2026-08-24 monthly 0.7 https://rjrindex.com/articles/five-decades-of-esophageal-cancer-mortality-in-the-united-states-shifting-patterns-by-sex-race-ag 2026-08-24 monthly 0.7 https://rjrindex.com/articles/glucagon-like-peptide-1-receptor-agonists-more-than-just-weight-loss-medications 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sylt-030-efficacy-and-safety-of-tislelizumab-plus-mfolfox6-versus-tislelizumab-plus-pof-paclitaxel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-and-economic-implications-of-venous-thromboembolism-in-pancreatic-cancer-patients-evidence 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-metabolic-and-lifestyle-risk-factors-on-hepatocellular-carcinoma-incidence-and-outcomes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/surgical-efficacy-of-neoadjuvant-mono-immunotherapy-for-t-sub4sub 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-effect-of-medicaid-expansion-on-time-to-treatment-and-survival-in-metastatic-colorectal-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/supporting-utility-and-representation-in-genomics-based-clinical-trial-enrollment-surge-interim-f 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-12-study-of-spevatamig-pt886-in-combination-with-gemcitabine-plus-nab-paclitaxel-gnp-in-f 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-systemic-therapy-plus-intraperitoneal-ip-paclitaxel-ptx-in-gastricgej-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/late-nonrelapse-mortality-a-hidden-risk-in-triplet-therapy-for-iidhi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-neoadjuvant-tqb2102-in-locally-advanced-or-early-human-epidermal-growth-facto 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-late-nonrelapse-mortality-a-hidden-risk-in-triplet-therapy-for-iidh 2026-08-24 monthly 0.7 https://rjrindex.com/articles/individual-patient-data-meta-analysis-of-consensus-molecular-subtypes-as-biomarkers-of-first-line-tr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/are-you-bereaved 2026-08-24 monthly 0.7 https://rjrindex.com/articles/carboplatin-for-premenopausal-triple-negative-breast-cancer-time-to-rethink-the-neoadjuvant-standar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/amivantamab-plus-lazertinib-in-atypical-iegfri-mutated 2026-08-24 monthly 0.7 https://rjrindex.com/articles/quizartinib-for-newly-diagnosed-iflt3i-internal-tandem-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/addition-of-carboplatin-to-sequential-taxane-anthracycline-neoadjuvant-chemotherapy-in-triple-negati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-five-year-outcomes-of-the-polarix-study-comparing-pola-r-chp-and-r-chop-in-patients-with-di 2026-08-24 monthly 0.7 https://rjrindex.com/articles/if-exercise-were-a-pill-wed-all-prescribe-it-to-patients-with-cancer-but-its-not 2026-08-24 monthly 0.7 https://rjrindex.com/articles/challenges-remaining-for-yttrium-90-radioembolization-the-case-for-standardized-dosimetry-and-compa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sun-sets-on-rituximabgemcitabineoxaliplatin-as-bispecific-antibodies-rise-the-sunmo-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sup177sup-lu-prostate-specific-membrane-antigen-neoadjuvant-to-stereotactic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-practical-assessment-and-management-of-vulnerabilities-in-older-patients-receiving-systemic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-glofitamab-plus-polatuzumab-vedotin-in-relapsedrefractory-large-b-cell-lymph 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-pulmonary-tumor-burden-in-favorable-histology-wilms-tumor-outcomes-a-report-from-the-chil 2026-08-24 monthly 0.7 https://rjrindex.com/articles/antibody-drug-conjugates-and-bispecific-antibodies-for-lymphoma-partners-of-convenience-or-a-perfec 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mosunetuzumab-plus-polatuzumab-vedotin-in-transplant-ineligible-refractoryrelapsed-large-b-cell-lym 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-man-at-the-bow 2026-08-24 monthly 0.7 https://rjrindex.com/articles/investigation-of-dna-damage-response-genes-validates-the-role-of-dna-repair-in-pediatric-cancer-risk 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-decoding-the-end-points-of-poly-adp-ribose-polymerase-inhibitor-trials-in-ovarian-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/decoding-the-end-points-of-poly-adp-ribose-polymerase-inhibitor-trials-in-ovarian-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/in-defense-of-adjuvant-cdk46-inhibitors-in-early-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-overall-survival-analysis-from-the-phase-ii-pharos-study-of-encorafenib-plus-binimetinib-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/molecular-characterization-informs-prognosis-in-patients-with-localized-ewing-sarcoma-a-report-from 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-revisiting-radium-223-in-oligometastatic-castration-sensitive-prostate-cancer-ravens-tria 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reflection 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-in-human-phase-iii-dose-escalation-and-expansion-study-of-zelenectide-pevedotin-in-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/us-food-and-drug-administration-approval-summary-imetelstat-for-selected-patients-with-low-to-inte 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reducing-daunorubicin-in-induction-therapy-in-children-with-b-lineage-all-with-favorable-prognosis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/five-year-outcomes-of-the-polarix-study-comparing-pola-r-chp-and-r-chop-in-patients-with-diffuse-lar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/revisiting-radium-223-in-oligometastatic-castration-sensitive-prostate-cancer-ravens-trial-insights 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-impact-of-lean-body-mass-based-oxaliplatin-dose-calculation-on-neurotoxicity-in-adjuvant-tr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trybeca-1-a-randomized-phase-iii-study-of-eryaspase-combined-with-chemotherapy-versus-chemotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/national-cancer-institutes-working-group-on-biochemically-recurrent-prostate-cancer-clinical-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-oxaliplatin-dosing-and-toxicity-a-cautionary-perspective-on-efficacy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comment-on-human-epidermal-growth-factor-receptor-2-low-metastatic-breast-cancer-treatment-costs-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/beyond-the-trials-real-world-considerations-for-sentinel-lymph-node-biopsy-omission-in-early-breast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/remission-assessment-by-circulating-tumor-dna-in-large-b-cell-lymphoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-comment-on-human-epidermal-growth-factor-receptor-2-low-metastatic-breast-cancer-treatment 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-long-term-continuous-nirogacestat-treatment-in-adults-with-desmoid-tumors-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/oxaliplatin-dosing-and-toxicity-a-cautionary-perspective-on-efficacy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/metformin-active-surveillance-trial-in-low-risk-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessing-remission-in-diffuse-large-b-cell-lymphoma-will-minimal-residual-disease-add-value-to-pos 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ruxolitinib-versus-best-available-therapy-in-patients-with-steroid-refractory-acute-graft-versus-hos 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-fighter-bigger-than-myeloma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/simultaneous-durvalumab-and-platinum-based-chemoradiotherapy-in-unresectable-stage-iii-non-small-cel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/fusing-oncolytic-virotherapy-with-cancer-immunotherapy-to-treat-therapy-resistant-melanoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tar-200-for-bacillus-calmette-guerin-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-resu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/five-year-follow-up-analysis-of-zuma-5-axicabtagene-ciloleucel-in-relapsedrefractory-indolent-non 2026-08-24 monthly 0.7 https://rjrindex.com/articles/next-generation-oncolytic-viruses-to-overcome-resistance-to-anti-pd-1-therapy-in-melanoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/rp1-combined-with-nivolumab-in-advanced-anti-pd-1-failed-melanoma-ignyte 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-inotch1i-a-potential-new-biomarker-in-the 2026-08-24 monthly 0.7 https://rjrindex.com/articles/single-arm-pivotal-studies-in-bacillus-calmette-guerin-unresponsive-non-muscle-invasive-bladder-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bridging-the-gap-incorporating-lifileucel-into-management-of-advanced-pd-1-blockade-resistant-melan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inotch1i-a-potential-new-biomarker-in-the-era-of-immunotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-efficacy-and-safety-of-lifileucel-tumor-infiltrating-lymphocyte-cell-therapy-in-patients-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/caution-in-interpreting-inotch1i-mutation-as-a-predicti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sirolimus-and-cyclosporine-with-post-transplant-cyclophosphamide-or-mycophenolate-mofetil-as-graft-v 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lymphedema-treatment-act-a-critical-step-for-cancer-survivors-but-unresolved-equity-gaps-persist 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-response-to-neoadjuvant-chemotherapy-and-breast-cancer-subtypes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-efficacy-and-safety-of-avutometinib-defactinib-in-recurrent-low-grade-serous-ovarian-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/deep-learning-model-for-breast-shear-wave-elastography-to-improve-breast-cancer-diagnosis-inspired 2026-08-24 monthly 0.7 https://rjrindex.com/articles/recurrence-patterns-of-esophageal-adenocarcinoma-in-the-phase-iii-esopec-trial-comparing-perioperati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/end-points-for-the-next-generation-bladder-sparing-perioperative-trials-for-patients-with-muscle-inv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-bl-b01d1-in-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inotuzumab-ozogamicin-then-blinatumomab-for-older-adults-with-newly-diagnosed-b-cell-all-alliance-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/precision-oncology-and-modernizing-evidence-standards-a-critical-commentary-on-the-cochrane-review 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bringing-trustworthy-artificial-intelligence-to-the-clinical-forefront-at-ijco 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-and-validation-of-an-artificial-intelligence-digital-pathology-biomarker-to-predict-bene 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bridging-the-gap-the-evolving-landscape-of-cns-management-in-small-cell-lung-cancer-prophylactic-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/foundation-model-for-predicting-prognosis-and-adjuvant-therapy-benefit-from-digital-pathology-in-gi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/response-to-neoadjuvant-chemotherapy-and-breast-cancer-subtypes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/apples-oranges-and-esopec-recurrence-patterns 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-identifying-patients-with-low-relapse-rate-despite-high-risk-estrogen-receptor-positivehum 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hippocampal-avoidance-during-prophylactic-cranial-irradiation-for-patients-with-small-cell-lung-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-ctla-4pd-l1-blockade-versus-surgery-chemotherapy-in-deficient-mismatch-repairmic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/primary-results-from-blood-and-marrow-transplant-clinical-trials-network-1702-clinical-transplant-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-beyond-1-month-a-broader-look-at-the-robomet-trial-results-and-robomet-revisited-is-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-machine-learning-predicts-oxaliplatin-benefit-in-early-colon-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/looking-for-the-best-allogeneic-donor-and-the-bmt-ctn-1702-study-noli-tempus-perdere 2026-08-24 monthly 0.7 https://rjrindex.com/articles/beyond-the-guided-missile-paradigm-embracing-the-complexity-of-antibody-drug-conjugates 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-systemic-anticancer-therapy-administration-near-the-end-of-life-with-health-care 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ziftomenib-in-relapsed-or-refractory-inpm1i-mutated-am 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pass-01-randomized-phase-ii-trial-of-modified-folfirinox-versus-gemcitabinenab-paclitaxel-and-mole 2026-08-24 monthly 0.7 https://rjrindex.com/articles/colorectal-specific-radiation-dose-and-chemotherapy-risk-for-subsequent-colorectal-malignancies-in-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-phase-ii-study-of-sup177sup-lu-dotatate-for-pr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-early-chemotherapy-intensification-with-escalated-beacopp-in-patients-with-advanced-stage-h 2026-08-24 monthly 0.7 https://rjrindex.com/articles/robomet-revisited-is-stereotactic-body-radiotherapy-truly-effective-for-painful-bone-metastases 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bridging-the-gap-molecular-profiling-to-guide-treatment-selection-in-metastatic-pancreatic-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/personalizing-chemotherapy-in-metastatic-pancreatic-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/beyond-1-month-a-broader-look-at-the-robomet-trial-results 2026-08-24 monthly 0.7 https://rjrindex.com/articles/modified-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-or-s-1-irinotecan-and-oxaliplatin-v 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-pass-01-randomized-phase-ii-trial-of-modified-folfirinox-versus-gemcitabinenab-paclitaxel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/investigating-racial-and-ethnic-disparities-along-the-care-cascade-for-older-adults-newly-diagnosed 2026-08-24 monthly 0.7 https://rjrindex.com/articles/us-food-and-drug-administration-approval-summary-ribociclib-with-an-aromatase-inhibitor-in-the-adju 2026-08-24 monthly 0.7 https://rjrindex.com/articles/acknowledgment-of-reviewers-2025 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treat-the-tumor-spare-the-esophagus-the-case-for-organ-preservation-in-locally-advanced-esophageal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/novel-systemic-anticancer-treatments-and-health-services-use-at-the-end-of-life-among-adults-with-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/postmastectomy-radiation-therapy-an-astro-asco-sso-clinical-practice-guideline 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-rethinking-treatment-priorities-in-estrogen-receptor-low-breast-cancer-and-cdk46-inhib 2026-08-24 monthly 0.7 https://rjrindex.com/articles/benefit-of-chemoradiotherapy-versus-chemotherapy-after-induction-therapy-for-conversion-of-unresecta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/rethinking-treatment-priorities-in-estrogen-receptor-low-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/why-adjuvant-treatment-with-a-cdk46-inhibitor-should-be-recommended-for-women-with-high-risk-breast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/single-agent-divarasib-in-patients-with-ikras-g12ci-po 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racial-and-ethnic-disparities-along-the-treatment-cascade-among-medicare-fee-for-service-beneficiari 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cdk46-inhibitors-in-estrogen-receptor-low-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/recalibrating-digital-predictions-uncovering-the-limits-of-the-mmai-prostate-lt-adt-predictive-mode 2026-08-24 monthly 0.7 https://rjrindex.com/articles/arsenic-trioxide-and-all-trans-retinoic-acid-combination-therapy-for-the-treatment-of-high-risk-acut 2026-08-24 monthly 0.7 https://rjrindex.com/articles/apollo-optimizing-the-treatment-of-high-risk-acute-promyelocytic-leukemia-with-all-trans-retinoic-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/taletrectinib-in-ros1-fusion-positive-non-small-cell-lung-cancer-promising-yet-premature 2026-08-24 monthly 0.7 https://rjrindex.com/articles/second-mitochondrial-activator-of-caspases-mimetics-accelerate-progression-of-locally-advanced-head 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pembrolizumab-plus-chemotherapy-versus-chemotherapy-as-perioperative-therapy-in-locally-advanced-gas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-ii-trial-of-pazopanib-versus-placebo-in-patients-with-advanced-extrapancreatic-neur 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-tar-200-for-bacillus-calmette-guerin-unresponsive-high-risk-non-muscle-invasive-bladder-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-human-epidermal-growth-factor-receptor-2-in-patients-with-metastatic-colorectal-cancer-tre 2026-08-24 monthly 0.7 https://rjrindex.com/articles/baseline-brain-metastasis-imbalance-in-trust-implications-for-interpreting-intracranial-efficacy-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/brain-imaging-surveillance-for-patients-with-metastatic-breast-cancer-a-randomized-clinical-trial-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/keynote-585-fails-while-matterhorn-succeeds-in-gastric-cancer-what-lessons-can-we-learn 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-baseline-brain-metastasis-imbalance-in-trust-implications-for-interpreting-intracranial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-dose-randomized-study-of-sunvozertinib-in-platinum-pretreated-non-small-cell-lung-cancer-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/xevinapant-or-placebo-plus-platinum-based-chemoradiotherapy-in-unresected-locally-advanced-squamous 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-recalibrating-digital-predictions-uncovering-the-limits-of-the-mmai-prostate-lt-adt-predi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nivolumab-and-ipilimumab-for-metastatic-castration-resistant-prostate-cancer-with-an-immunogenic-sig 2026-08-24 monthly 0.7 https://rjrindex.com/articles/identifying-patients-with-low-relapse-rate-despite-high-risk-estrogen-receptor-positivehuman-epider 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-prospective-study-of-supplemental-screening-with-contrast-enhanced-mammography-in-women-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-pediatric-and-adolescent-considerations-for-the-revised-asco-guidelines 2026-08-24 monthly 0.7 https://rjrindex.com/articles/brown-paper-bags 2026-08-24 monthly 0.7 https://rjrindex.com/articles/precision-and-combination-strategies-for-immune-checkpoint-inhibitors-in-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-study-of-sup177sup-lu-dotatate-for-progressive 2026-08-24 monthly 0.7 https://rjrindex.com/articles/us-food-and-drug-administration-approval-summary-inavolisib-with-palbociclib-and-fulvestrant-for-en 2026-08-24 monthly 0.7 https://rjrindex.com/articles/is-there-a-role-for-mifamurtide-in-nonmetastatic-high-grade-osteosarcoma-results-from-the-italian-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-ukall-2011-flawed-noninferiority-and-overlooked-interactions-undermine-conclusions-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/focal-boost-to-the-intraprostatic-tumor-in-external-beam-radiotherapy-for-patients-with-localized-pr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/understanding-the-potential-importance-of-pharmacokinetic-variability-in-the-setting-of-all 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pediatric-and-adolescent-considerations-for-the-revised-asco-guidelines 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-iii-study-of-mediastinal-lymph-node-dissection-for-ground-glass-opacity-dominant-lung-adenocar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mediastinal-nodal-evaluation-may-be-safely-omitted-in-select-patients-with-ground-glass-dominant-lun 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ukall-2011-flawed-noninferiority-and-overlooked-interactions-undermine-conclusions 2026-08-24 monthly 0.7 https://rjrindex.com/articles/afatinib-dose-reduction-and-pseudo-acute-kidney-injury 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-isatuximab-subcutaneous-by-on-body-injector-versus-isatuximab-intravenous-plus-pomalidomide 2026-08-24 monthly 0.7 https://rjrindex.com/articles/modern-targeted-radiation-in-patients-with-brain-metastases-from-small-cell-lung-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reading-the-room-a-joint-perspective-from-a-scientist-and-patient-partnered-working-group-on-the-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-afatinib-dose-reduction-and-pseudo-acute-kidney-injury 2026-08-24 monthly 0.7 https://rjrindex.com/articles/antibody-based-therapies-for-the-treatment-of-hodgkin-lymphoma-in-older-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/stereotactic-radiosurgery-in-patients-with-small-cell-lung-cancer-and-1-10-brain-metastases-a-multi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/muscle-invasive-bladder-cancer-a-watershed-moment 2026-08-24 monthly 0.7 https://rjrindex.com/articles/positron-emission-tomography-guided-brentuximab-vedotin-etoposide-cyclophosphamide-doxorubicin-d 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nivolumab-avd-versus-brentuximab-vedotin-avd-in-older-patients-with-advanced-stage-classic-hodgkin-l 2026-08-24 monthly 0.7 https://rjrindex.com/articles/germline-pathogeniclikely-pathogenic-mutations-and-subsequent-neoplasms-among-childhood-cancer-surv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dual-immune-check-point-blockade-in-imgmti-unmethylate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/health-outcomes-beyond-age-50-years-in-survivors-of-childhood-cancer-a-report-from-the-childhood-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-i-dose-escalation-results-for-the-delta-like-ligand-3cd3-igg-like-t-cell-engager-obrixtamig 2026-08-24 monthly 0.7 https://rjrindex.com/articles/why-is-earlier-detection-the-key-to-reducing-pancreatic-cancer-so-challenging-despite-technologica 2026-08-24 monthly 0.7 https://rjrindex.com/articles/caution-needed-before-adopting-reduced-dose-elective-neck-irradiation-in-head-and-neck-cancer-a-res 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inconsistent-and-inaccurate-cancer-clinical-trial-reporting-of-venous-and-arterial-thrombotic-events 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-survival-and-biomarker-analysis-evaluating-neoadjuvant-plus-adjuvant-relatlimab-anti-lag3 2026-08-24 monthly 0.7 https://rjrindex.com/articles/primary-analysis-of-epik-oengot-ov61-alpelisib-plus-olaparib-versus-chemotherapy-in-platinum-resis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adagio-a-phase-iib-open-label-single-arm-multicenter-study-assessing-the-efficacy-and-safety-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/diabetes-and-colorectal-cancer-risk-and-survival-according-to-tumor-immunity-status 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-osimertinib-a-step-ahead-or-just-a-step 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-caution-needed-before-adopting-reduced-dose-elective-neck-irradiation-in-head-and-neck-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-and-validation-of-a-cell-free-dna-fragmentomics-based-model-for-early-detection-of-pancr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-osimertinib-for-resectable-iegfri-mutated 2026-08-24 monthly 0.7 https://rjrindex.com/articles/response-adapted-surgical-and-radiotherapy-de-escalation-in-resectable-cutaneous-squamous-cell-cance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/us-food-and-drug-administration-approval-summary-trastuzumab-deruxtecan-for-the-treatment-of-adult 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-bo-112-plus-pembrolizumab-for-patients-with-anti-pd-1-resistant-advanced-melanoma-phase-ii 2026-08-24 monthly 0.7 https://rjrindex.com/articles/random-assignment-but-without-comparison-a-missed-opportunity 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-randomized-phase-ii-study-of-nab-paclitaxel-and-gemcitabine-with-or-without-tocilizumab-as 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-avutometinib-defactinib-in-recurrent-low-grade-serous-ovarian-cancer-prima 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-allogeneic-chimeric-antigen-receptor-t-cell-persistence-in-relapsedrefractory-large-b-ce 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-follow-up-of-real-world-adjuvant-anti-pd-1-checkpoint-inhibition-and-targeted-therapy-in-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patritumab-deruxtecan-her3-dxd-mk-1022-in-non-small-cell-lung-cancer-after-platinum-based-chemoth 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-5-year-remission-and-survival-after-treatment-with-ciltacabtagene-autoleucel-in-cartitu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/post-transplant-cyclophosphamide-based-graft-versus-host-disease-prophylaxis-after-mismatched-unrela 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bo-112-plus-pembrolizumab-for-patients-with-anti-pd-1-resistant-advanced-melanoma-phase-ii-clinical 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-phase-iii-trial-of-pirtobrutinib-versus-idelalisibrituximab-or-bendamustinerituximab-in-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/guidance-for-ijcoi-authors-on-subgroup-representation-and-reporting 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-random-assignment-but-without-comparison-a-missed-opportunity 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-optimizing-allogeneic-chimeric-antigen-receptor-t-cell-persistence-in-relapsedrefractory 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-cure-a-cure-my-kingdom-for-a-cure 2026-08-24 monthly 0.7 https://rjrindex.com/articles/retraction-disability-adjusted-life-years-from-human-papillomavirus-related-oral-cavity-and-pharynx 2026-08-24 monthly 0.7 https://rjrindex.com/articles/totality-of-the-evidence-optimizing-dosage-selection-strategies-in-oncology 2026-08-24 monthly 0.7 https://rjrindex.com/articles/therapy-for-stage-iv-non-small-cell-lung-cancer-without-driver-alterations-asco-living-guideline-v 2026-08-24 monthly 0.7 https://rjrindex.com/articles/rewriting-risk-a-data-driven-look-at-myeloma-genetics 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-de-novo-oligometastatic-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/international-myeloma-societyinternational-myeloma-working-group-consensus-recommendations-on-the-d 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-inappropriate-conclusions-on-surrogate-end-points-in-early-breast-cancer-trials-and-met 2026-08-24 monthly 0.7 https://rjrindex.com/articles/co-occurrence-of-cytogenetic-abnormalities-and-high-risk-disease-in-newly-diagnosed-and-relapsedref 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inappropriate-conclusions-on-surrogate-end-points-in-early-breast-cancer-trials 2026-08-24 monthly 0.7 https://rjrindex.com/articles/breastfeeding-after-hormone-receptor-positive-breast-cancer-results-from-the-positive-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-sharper-focus-greater-comfort-lessons-from-the-robomet-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-art-of-the-art-of-oncology 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lisocabtagene-maraleucel-versus-standard-of-care-for-second-line-relapsedrefractory-large-b-cell-ly 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-frontline-triplet-regimens-with-a-hypomethylating-agent-venetoclax-and-isocitrate-dehy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/microbiome-modulation-for-the-treatment-of-solid-neoplasms 2026-08-24 monthly 0.7 https://rjrindex.com/articles/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-living-guideline-vers-2 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-hematopoietic-stem-cell-transplantation-outcomes-for-high-risk-aml-a-report-from-the-child 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multisite-randomized-trial-of-inpatient-palliative-care-intervention-for-patients-undergoing-hematop 2026-08-24 monthly 0.7 https://rjrindex.com/articles/methodologic-considerations-in-assessing-invasive-disease-free-survival-as-a-surrogate-end-point-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cancer-surveillance-in-the-united-states-in-jeopardy-leveraging-21st-century-technology-to-enhance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/camrelizumab-plus-famitinib-versus-camrelizumab-alone-and-investigators-choice-of-chemotherapy-in-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-ii-study-of-concurrent-versus-sequential-pembrolizumab-in-combination-with-chemorad 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-lean-body-mass-based-oxaliplatin-dose-calculation-on-neurotoxicity-in-adjuvant-treatment-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-follow-up-of-e3311-an-ecog-acrin-cancer-research-group-phase-ii-trial-of-transoral-surger 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-outcomes-after-transoral-robotic-surgery-for-oropharyngeal-carcinoma-reflections-on-the 2026-08-24 monthly 0.7 https://rjrindex.com/articles/surgery-versus-ablation-for-hepatocellular-carcinoma-a-randomized-controlled-trial-surf-rct-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ruxolitinib-in-patients-with-corticosteroid-refractory-or-corticosteroid-dependent-chronic-graft-ver 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tumor-intrinsic-and-microenvironmental-determinants-of-impaired-antitumor-immunity-in-chromophobe-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/should-we-screen-for-malignancies-in-people-with-ataxia-telangiectasia 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-benefit-and-safety-of-reduced-elective-dose-in-definitive-radiotherapy-for-head-and-neck-sq 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-mid-treatment-positron-emission-tomography-adaptive-radiotherapy-in-stage-iii-non-small-cel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-randomized-open-label-phase-iii-study-of-tilsotolimod-in-combination-with-ipilimumab-vers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/azacitidine-venetoclax-and-revumenib-for-newly-diagnosed-inpm1i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-optimizing-outcomes-after-transoral-robotic-surgery-for-oropharyngeal-carcinoma-reflectio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/glofitamab-combined-with-pola-r-chp-or-r-chop-as-first-therapy-in-younger-patients-with-high-risk-la 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-international-myeloma-societyinternational-myeloma-working-group-consensus-recommendations 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-omission-of-radiotherapy-or-not 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-i-study-of-sup131sup-i-metaiodobenzylguanidine-with-dinutuximab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/isatuximab-subcutaneous-by-on-body-injector-versus-isatuximab-intravenous-plus-pomalidomide-and-dexa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/overall-survival-after-allogeneic-transplantation-in-advanced-cutaneous-t-cell-lymphomas-cutallo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lenvatinib-plus-pembrolizumab-and-chemotherapy-versus-chemotherapy-in-advanced-metastatic-gastroesop 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dendrimer-nanoparticle-dep-delivery-of-topoisomerase-i-inhibitor-sn38-dep-sn38-safety-tolerab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-dynamic-financial-impacts-among-adolescents-and-young-adults-with-cancer-a-longitudinal-m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-fertility-preservation-in-people-with-cancer-asco-guideline-update 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-therapy-for-locally-advanced-rectal-cancer-omission-of-radiotherapy-or-not 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-iii-trial-of-pirtobrutinib-versus-idelalisibrituximab-or-bendamustinerituximab-in-covalent-b 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pasritamig-a-first-in-class-bispecific-t-cell-engager-targeting-human-kallikrein-2-in-metastatic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adoptive-cell-transfer-of-tumor-infiltrating-lymphocytes-for-metastatic-acral-lentiginous-melanoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/enduring-economic-effects-of-a-cancer-diagnosis-in-adolescence-and-young-adulthood 2026-08-24 monthly 0.7 https://rjrindex.com/articles/why-we-do-not-recommend-that-women-with-breast-cancer-receive-adjuvant-treatment-with-a-cdk46-inhib 2026-08-24 monthly 0.7 https://rjrindex.com/articles/zipalertinib-in-patients-with-epidermal-growth-factor-receptor-exon-20-insertion-positive-non-small 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-alliance-a091802-randomized-trial-of-avelumab-plus-cetuximab-versus-avelumab-alone-in-adv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tumor-treating-fields-open-the-door-to-progress-for-patients-with-locally-advanced-pancreatic-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-comment-on-the-study-of-nrg258-limitations-and-future-directions 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-benefit-of-palliative-oophorectomy-for-patients-with-ovarian-metastasis-from-baseline-metas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-from-first-in-human-phase-i-study-of-a-novel-cd19-1xx-chimeric-antigen-receptor-with-calibra 2026-08-24 monthly 0.7 https://rjrindex.com/articles/zanubrutinib-and-venetoclax-for-patients-with-treatment-naive-chronic-lymphocytic-leukemiasmall-lym 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comment-on-the-study-of-nrg258-limitations-and-future-directions 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mindfulness-and-tai-chi-for-cancer-health-match-study-primary-outcomes-of-a-preference-based-mult 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tumor-treating-fields-with-gemcitabine-and-nab-paclitaxel-for-locally-advanced-pancreatic-adenocarci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nephrotoxicity-surveillance-for-childhood-and-young-adult-survivors-of-cancer-recommendations-from 2026-08-24 monthly 0.7 https://rjrindex.com/articles/calibrating-chimeric-antigen-receptor-car-signaling-to-improve-car-t-cell-therapies 2026-08-24 monthly 0.7 https://rjrindex.com/articles/five-year-survival-outcomes-with-atezolizumab-after-chemotherapy-in-resected-stage-ib-iiia-non-small 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-iii-study-of-adaptive-manufactured-lentiviral-anti-cd20anti-cd19-chimeric-antigen-receptor-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-of-low-value-cancer-treatments-in-medicare-advantage-versus-traditional-medicare 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-whipple-of-choice 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-chimeric-antigen-receptor-t-cell-therapy-for-mantle-cell-lymphoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/systemic-therapy-in-patients-with-metastatic-castration-resistant-prostate-cancer-asco-guideline-up 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bmt-care-app-a-randomized-controlled-trial-of-a-psychosocial-digital-application-for-caregivers-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-overall-survival-and-long-term-safety-with-ripretinib-versus-sunitinib-in-patients-with-gi-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prodige-29-ucgi-26-neopan-a-phase-iii-randomized-trial-comparing-chemotherapy-with-folfirinox-or 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mantle-cell-lymphoma-optimal-treatment-with-bruton-tyrosine-kinase-targeted-approaches 2026-08-24 monthly 0.7 https://rjrindex.com/articles/retraction-phase-1-clinical-trial-of-epcam-car-t-cell-therapy-in-patients-with-gastrointestinal-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/acalabrutinib-plus-bendamustine-rituximab-in-untreated-mantle-cell-lymphoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/financial-toxicity-in-cancer-clinical-trials-an-issue-in-need-of-clarity-and-solutions 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-study-no-limit-wjog13320g-of-first-line-nivolumab-plus-low-dose-ipilimumab-for-microsate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cost-and-cost-effectiveness-of-treating-human-epidermal-growth-factor-receptor-2-low-metastatic-brea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/overall-survival-analysis-of-the-phase-iii-codebreak-300-study-of-sotorasib-plus-panitumumab-versus 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-and-validation-of-a-novel-prediction-model-for-hearing-loss-from-cisplatin-chemotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-iii-trial-of-ramucirumab-beyond-progression-plus-irinotecan-in-patients-with-ramuci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adjuvant-treatment-options-and-modalities-in-pancreatic-adenocarcinoma-insights-from-espac4 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-ib-clinical-trial-of-db-020-intratympanic-injections-to-reduce-high-dose-cisplatin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-adjuvant-treatment-options-and-modalities-in-pancreatic-adenocarcinoma-insights-from-espa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sharper-focus-greater-comfort-lessons-from-the-robomet-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/overall-survival-and-the-evolving-benefit-risk-assessment-for-poly-adp-ribose-polymerase-inhibitor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dose-escalated-stereotactic-versus-conventional-radiotherapy-for-painful-bone-metastases-robomet 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-phase-trials-in-ijournal-of-clinical-oncologyi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/transcription-phone-call-2018 2026-08-24 monthly 0.7 https://rjrindex.com/articles/therapy-for-diffuse-astrocytic-and-oligodendroglial-tumors-in-adults-asco-sno-guideline-rapid-recom 2026-08-24 monthly 0.7 https://rjrindex.com/articles/practical-guidelines-for-the-treatment-of-gestational-trophoblastic-disease-collaboration-of-the-eu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/rationale-for-investigation-of-neoadjuvant-chemoimmunotherapy-before-chemoradiation-in-unresectable 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hypofractionated-dose-escalated-radiation-versus-conventionally-fractionated-radiation-for-localize 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-assessing-clinical-utility-of-datopotamab-deruxtecan-versus-chemotherapy-for-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessing-clinical-utility-of-datopotamab-deruxtecan-versus-chemotherapy-for-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/every-patient-is-unique-and-deserves-the-best-the-present-and-future-treatment-landscape-of-uncommo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/second-line-endocrine-therapy-with-or-without-palbociclib-rechallenge-in-patients-with-hormone-recep 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pragmatic-randomized-study-of-afatinib-versus-chemotherapy-for-patients-with-non-small-cell-lung-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characteristics-of-patients-and-prognostic-factors-across-treatment-lines-in-metastatic-colorectal-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterization-and-clinical-implications-of-p53-dysfunction-in-patients-with-myelodysplastic-syndr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-ii-study-of-nab-paclitaxel-and-gemcitabine-with-or-without-tocilizumab-as-first-lin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-radium-223-and-stereotactic-ablative-radiotherapy-versus-stereotactic-ablative-radiother 2026-08-24 monthly 0.7 https://rjrindex.com/articles/becotatug-vedotin-vs-chemotherapy-in-pre-heavily-treated-advanced-nasopharyngeal-carcinoma-a-rando 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sacituzumab-govitecan-sg-pembrolizumab-pembro-vs-chemotherapy-chemo-pembro-in-previously-u 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trust-trial-of-radical-upfront-surgical-therapy-in-advanced-ovarian-cancer-engot-ov33agoovar-op7 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-genetic-information-and-family-testing-gift-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-reduced-port-laparoscopic-surgery-for-patients-with-colon-and-upper-rectal-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/promoting-reasonable-career-expectations-and-maximizing-professional-fulfillment-for-academic-oncolo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/toxicity-within-6-months-of-heterogeneous-fluorodeoxyglucose-guided-radiotherapy-dose-escalation-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/anlotinib-versus-bevacizumab-added-to-standard-first-line-chemotherapy-among-patients-with-rasbraf 2026-08-24 monthly 0.7 https://rjrindex.com/articles/novel-postneoadjuvant-prognostic-breast-cancer-staging-system 2026-08-24 monthly 0.7 https://rjrindex.com/articles/camizestrant-cdk46-inhibitor-cdk46i-for-the-treatment-of-emergent-iesr1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/an-international-multicenter-prospective-randomized-trial-of-adjuvant-chemotherapy-for-stage-ia-ii 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cancer-care-beyond-walls-ccbw-a-randomized-pragmatic-trial-of-home-based-versus-in-clinic-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/aspirin-as-secondary-prevention-for-colorectal-cancer-liver-metastases-asac-a-multicenter-random 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sequential-infusion-of-mesenchymal-stem-cell-for-graft-versus-host-disease-prevention-in-haploidenti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/perioperative-nivolumab-nivo-vs-placebo-pbo-in-patients-pts-with-resectable-nsclc-updated-sur 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pro-active-results-of-a-pragmatic-phase-iv-randomized-trial-comparing-the-effectiveness-of-prophyla 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hematopoietic-stem-cell-transplantation-outcomes-for-high-risk-aml-a-report-from-the-childrens-onc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/primary-analysis-of-the-eortc-2139-mgcolumbus-ad-trial-a-randomized-trial-of-adjuvant-encorafenib 2026-08-24 monthly 0.7 https://rjrindex.com/articles/event-free-survival-efs-in-matterhorn-a-randomized-phase-3-study-of-durvalumab-plus-5-fluorourac 2026-08-24 monthly 0.7 https://rjrindex.com/articles/disitamab-vedotin-dv-plus-toripalimab-tor-and-chemotherapy-ctrastuzumab-tra-as-first-line 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-randomized-phase-iii-trial-of-the-impact-of-a-structured-exercise-program-on-disease-free-survival 2026-08-24 monthly 0.7 https://rjrindex.com/articles/jmt101-in-combination-with-irinotecan-and-sg001-versus-regorafenib-in-patients-with-metastatic-color 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-ii-trial-investigating-whether-atezolizumab-after-chemoradiotherapy-crt-prolongs 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sup18sup-f-labeled-fluorodeoxyglucose-positron-emiss 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-trial-of-standard-chemotherapy-alone-or-combined-with-atezolizumab-as-adjuvant-therapy-fo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/r-alps-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-clinical-trial-of-tqb2 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pembrolizumab-with-chemoradiotherapy-in-patients-with-high-risk-locally-advanced-cervical-cancer-fi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-anti-b-cell-maturation-antigen-chimeric-antigen-receptor-t-cell-for-the-treat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-phase-ii-nibit-ml1-study-of-nivolumab-plus-ipilimumab-and-astx727-or-nivolumab-plus-ipilimumab-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/de-escalated-neoadjuvant-taxane-plus-trastuzumab-and-pertuzumab-with-or-without-carboplatin-in-her2 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-from-verify-a-phase-3-double-blind-placebo-pbo-controlled-study-of-rusfertide-for-treat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nivopostop-gortec-2018-01-a-phase-iii-randomized-trial-of-adjuvant-nivolumab-added-to-radio-chemo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-ii-study-of-neoadjuvant-neoadj-anti-pd-1-dostarlimab-d-vs-d-anti-tim-3-cobol 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-stupp-regimen-with-or-without-anlotinib-for-newly-diagnosed-glioblastoma-res 2026-08-24 monthly 0.7 https://rjrindex.com/articles/academic-medical-centers-and-asco-recommendations-starting-a-difficult-discussion 2026-08-24 monthly 0.7 https://rjrindex.com/articles/enlighted-phase-3-study-interim-results-of-efficacy-and-safety-of-padeliporfin-vascular-targeted-ph 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-importance-of-defining-recurrence-in-hepatocellular-carcinoma-local-or-both-local-and-oth 2026-08-24 monthly 0.7 https://rjrindex.com/articles/rosella-a-phase-3-study-of-relacorilant-in-combination-with-nab-paclitaxel-versus-nab-paclitaxel-mo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-randomized-phase-2-trial-of-encorafenib-binimetinib-nivolumab-vs-ipilimumab-nivolumab-in-bra 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trastuzumab-deruxtecan-t-dxd-vs-ramucirumab-ram-paclitaxel-ptx-in-second-line-treatment-of-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/panitumumab-retreatment-followed-by-regorafenib-versus-the-reverse-sequence-in-chemorefractory-metas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-double-blind-placebo-controlled-randomized-phase-iii-trial-of-fulvestrant-and-ipatasertib-as-treat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/napoli-3-a-phase-3-study-of-nalirifox-in-patients-with-metastatic-pancreatic-ductal-adenocarcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/importance-of-defining-recurrence-in-hepatocellular-carcinoma-local-or-both-local-and-other-intrahe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pd-1-blockade-with-toripalimab-incorporated-into-induction-chemotherapy-and-radiotherapy-with-or-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nivolumab-plus-relatlimab-vs-nivolumab-alone-for-the-adjuvant-treatment-of-completely-resected-stage 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tarlatamab-versus-chemotherapy-ctx-as-second-line-2l-treatment-for-small-cell-lung-cancer-sclc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-reproducibility-of-clinically-meaningful-change-in-physical-capacity-tested-by-online-6-mi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/firstengot-ov44-a-phase-3-clinical-trial-of-dostarlimab-dost-and-niraparib-nira-in-first-line 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pragmatica-lung-swog-s2302-a-prospective-randomized-study-of-ramucirumab-plus-pembrolizumab-vers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lower-dose-versus-standard-dose-abiraterone-in-patients-with-metastatic-castration-resistant-prostat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-every-patient-is-unique-and-deserves-the-best-the-present-and-future-treatment-landscape-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/writing-a-medical-memoir-lessons-from-a-long-steep-road 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sentinel-lymph-node-biopsy-versus-pelvic-lymphadenectomy-in-cervical-cancer-the-phenix-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-1-year-versus-minimum-2-years-of-anti-pd1-based-immunotherapy-as-first-line-treatment 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trastuzumab-deruxtecan-t-dxd-pertuzumab-p-vs-taxane-trastuzumab-pertuzumab-thp-for-first 2026-08-24 monthly 0.7 https://rjrindex.com/articles/vepdegestrant-a-protac-estrogen-receptor-er-degrader-vs-fulvestrant-in-er-positivehuman-epiderm 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reproducibility-of-clinically-meaningful-change-in-physical-capacity-tested-by-online-6-minute-walk 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-empirical-dietary-inflammatory-pattern-edip-and-survival-in-patients-with-stag 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-folfirinox-chemotherapy-for-resectable-pancreatic-adenocarcinoma-a-multicenter-random 2026-08-24 monthly 0.7 https://rjrindex.com/articles/overall-survival-with-neoadjuvant-nivolumab-nivo-chemotherapy-chemo-in-patients-with-resectabl 2026-08-24 monthly 0.7 https://rjrindex.com/articles/an-open-label-randomized-non-inferiority-trial-comparing-adjuvant-platinum-plus-paclitaxel-to-platin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/campass-benmelstobart-in-combination-with-anlotinib-vs-pembrolizumab-in-the-first-line-treatment-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/savolitinib-savo-combined-with-osimertinib-osi-versus-chemotherapy-chemo-in-egfr-mutant-egfrm 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-randomized-study-of-neoadjuvant-pembrolizumab-p-alone-or-in-combination-with-vidutolimo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/panova-3-phase-3-study-of-tumor-treating-fields-ttfields-with-gemcitabine-and-nab-paclitaxel-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-of-a-randomized-phase-iii-trial-of-pre-operative-chemotherapy-with-mfolfirinox-or-paxg-regim 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nrg-br003-a-randomized-phase-iii-trial-comparing-doxorubicin-plus-cyclophosphamide-followed-by-week 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-line-encorafenib-cetuximab-mfolfox6-in-braf-v600e-mutant-metastatic-colorectal-cancer-bre 2026-08-24 monthly 0.7 https://rjrindex.com/articles/anesthesia-type-during-surgery-for-treatment-of-biologically-aggressive-cancers-results-of-the-ga-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mitomycin-plus-bcg-as-adjuvant-intravesical-therapy-for-high-risk-non-muscle-invasive-bladder-cance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-3-amplitude-trial-niraparib-nira-and-abiraterone-acetate-plus-prednisone-aap-for-metastat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-of-a-phase-i-clinical-trial-of-cetuximab-biosimilar-rph-002 2026-08-24 monthly 0.7 https://rjrindex.com/articles/eosinophilia-and-basophilia-in-essential-thrombocythemia-and-polycythemia-vera-clinical-genetic-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/decoding-nampt-and-tigar-a-molecular-blueprint-for-reprogramming-tumor-metabolism-and-immunity 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nimotuzumab-plus-chemotherapy-in-the-posterior-line-treatment-for-lung-adenocarcinoma-with-third-gen 2026-08-24 monthly 0.7 https://rjrindex.com/articles/complementary-value-of-a-digital-pathology-biomarker-to-post-surgery-circulating-tumor-dna-in-risk-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-frequency-of-driver-mutations-in-non-small-cell-lung-cancer-patients-the-turkish-nation-wide-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/frailty-index-as-a-predictor-of-postoperative-outcomes-in-oral-carcinoma-patients-undergoing-surgery 2026-08-24 monthly 0.7 https://rjrindex.com/articles/economic-burden-of-cytokine-release-syndrome-in-older-adults-and-underserved-populations-a-nationwi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/estrogen-receptor-er-expression-on-circulating-tumor-cells-ctcs-and-cell-free-dna-cfdna-mutati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-neoadjuvant-immunotherapy-in-head-and-neck-squamous-carcinoma-hnscc-a-systematic-revi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/factors-influencing-surgical-treatment-of-adenoid-cystic-carcinoma-of-the-head-and-neck-a-national 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-of-management-of-cervical-lymph-node-metastases-in-differentiated-thyroid-carcinoma-experie 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-role-of-estrogen-receptor-er-expression-in-breast-cancer-bc-metastases-and-its-dynami 2026-08-24 monthly 0.7 https://rjrindex.com/articles/molecular-and-prognostic-convergence-of-hrher2-metastatic-breast-cancer-mbc-to-a-tnbc-like-prof 2026-08-24 monthly 0.7 https://rjrindex.com/articles/m6a-methylated-lncrnas-to-facilitate-keratinocyte-pyroptosis-and-to-spark-cutaneous-toxicities-assoc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-and-disparities-in-thyroid-cancer-mortality-in-the-united-states-a-24-year-retrospective-ana 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mfolfox6-bevacizumab-pd-1-monoclonal-antibody-vs-mfolfox6-in-locally-advanced-pmmrmss-crc-a-m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/incidence-and-risk-factors-for-venous-thromboembolism-after-car-t-cell-therapy-a-systematic-review 2026-08-24 monthly 0.7 https://rjrindex.com/articles/perturbational-single-cell-rna-sequencing-of-patient-tumors-in-merkel-cell-and-small-cell-lung-carci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-12-study-of-tsn222-a-novel-dual-action-tumor-immune-agonist-datia-in-patients-with-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/relationship-between-immune-mediated-adverse-events-and-clinical-outcomes-in-patients-with-metastati-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-in-patients-with-neuroendocrine-tumors-and-concomitant-protein-energy-malnutrition 2026-08-24 monthly 0.7 https://rjrindex.com/articles/systemic-therapies-for-advanced-melanoma-after-immunotherapy-failure-efficacy-and-safety-insights 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preoperative-treatment-for-potentially-resectable-esophageal-cancer-insights-from-a-nationwide-real 2026-08-24 monthly 0.7 https://rjrindex.com/articles/precision-medicine-research-on-chemo-immunotherapy-combination-treatment-for-locally-advanced-or-met 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-treatment-practices-and-outcomes-of-metastatic-merkel-cell-carcinoma-a-retrospective-stu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-of-targeted-therapy-healthcare-costs-and-survival-with-large-panel-testing-narrow-testing-or 2026-08-24 monthly 0.7 https://rjrindex.com/articles/monitoring-pd-l1-expression-in-cancer-associated-macrophage-like-cells-as-predictor-of-clinical-outc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-study-of-hlx07-plus-serplulimab-with-or-without-chemotherapy-versus-serplulimab-plus-chemo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-prospective-non-randomized-clinical-study-to-evaluate-the-efficacy-of-intraperitoneal-pd-1-monoclo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/microbial-metabolic-pathways-to-abrogate-immunotherapy-toxicity-and-promote-anti-tumor-response-in-m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/extracellular-vesicle-digital-scoring-assay-for-assessment-of-treatment-responses-in-hepatocellular 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hyponatremia-as-a-predictor-of-in-hospital-mortality-in-cirrhotic-and-non-cirrhotic-hepatocellular-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/feasibility-of-door-to-door-hpv-dna-screening-using-self-collected-vaginal-swabs-for-early-detection 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nimotuzumab-with-chemoradiotherapy-for-newly-diagnosed-high-risk-locally-advanced-squamous-cervica 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessment-of-tumors-blood-and-ascites-to-establish-correlations-with-treatment-benefit-in-platinu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sociodemographic-and-clinicopathological-factors-affecting-survival-in-young-women-real-world-data 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-rucaparib-on-circadian-rhythms-and-adverse-events-in-ovarian-cancer-insights-from-the-mam 2026-08-24 monthly 0.7 https://rjrindex.com/articles/applying-learning-science-principles-lsp-through-a-simulation-session-sim-for-oncology-trainees 2026-08-24 monthly 0.7 https://rjrindex.com/articles/struma-ovarii-an-ncdb-retrospective-study-of-demographic-and-socioeconomic-factors 2026-08-24 monthly 0.7 https://rjrindex.com/articles/socioeconomic-disparities-in-access-to-and-outcomes-of-liver-transplantation-lt-for-hepatocellular 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hif-family-transcription-factor-expression-in-a-cohort-of-4362-patients-with-renal-cell-carcinoma-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-role-of-pre-treatment-eosinophilia-in-nsclc-patients-undergoing-immune-checkpoint-inhibit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characteristics-and-outcome-of-breast-cancers-diagnosed-in-patients-with-germline-atm-mutations 2026-08-24 monthly 0.7 https://rjrindex.com/articles/socioeconomic-and-clinical-characteristics-of-large-cell-medulloblastoma-a-comprehensive-ncdb-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trial-in-progress-feasibility-of-csf-and-plasma-ctdna-in-braf-altered-glioma-during-treatment-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-2021-united-states-cancer-screening-guideline-changes-on-racial-and-ethnic-differences-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-quality-of-life-qol-for-patients-pts-with-metastatic-renal-cell-carcinoma-mrcc-trea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-in-non-hodgkin-lymphoma-and-sepsis-related-mortality-among-older-adults-1999-2020-a-cdc-won 2026-08-24 monthly 0.7 https://rjrindex.com/articles/design-of-a-first-in-human-multicenter-open-label-study-of-zw171-a-mesothelin-x-cd3-targeting-bispe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-12-study-of-fog-001-a-first-in-class-direct-v-catenin-tcf-inhibitor-in-patients-with-col 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immunonet-a-multicenter-open-label-proof-of-concept-phase-ii-trial-evaluating-np137-as-add-on-the 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lurbinectedin-with-immunotherapy-in-extensive-stage-small-cell-lung-cancer-current-insights-and-fut 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-efficacy-and-safety-of-zurlectrectinib-in-adult-patients-pts-with-locally-advanced-or-meta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-insights-into-advanced-combined-small-cell-lung-cancer-clinical-characteristics-and-ther 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effect-of-krt3-on-colorectal-cancer-growth-through-regulation-glycolysis-via-the-cebpd-lrrc8a-akt-si 2026-08-24 monthly 0.7 https://rjrindex.com/articles/relationship-between-folr1-expression-and-pan-cancer-subgroup-of-tumors-with-specific-transcriptomic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-efficacy-and-safety-of-front-line-cdk46-inhibitor-therapy-in-hrher2-advanced-breast-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-prediction-of-prognosis-in-advanced-solid-tumor-patients-using-tumor-growth-rates-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-new-option-for-post-cdk46is-resistance-era-multicenter-real-world-study-of-anlotinib-based-combi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/disparities-in-glp-1-receptor-agonist-prescriptions-among-breast-cancer-survivors-with-type-2-diabet 2026-08-24 monthly 0.7 https://rjrindex.com/articles/does-frailty-modulate-the-predictive-value-of-performance-status-in-older-adults-with-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-acute-toxicity-questionnaire-adherence-of-nonmetastatic-patients-treated-in-an-infusio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-of-stages-ii-iv-gastric-cancer-a-13-year-single-center-experience 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immune-checkpoint-inhibitors-for-ovarian-cancer-a-retrospective-analysis-of-efficacy-and-tolerabili 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prevalence-of-pathogenic-germline-variants-in-hereditary-breastovarian-cancer-patients-at-the-natio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/meta-analysis-of-55-studies-examining-the-association-between-bmi-and-lung-cancer-risk-in-non-smoker 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sars-cov-2-infection-risk-and-covid-19-prevalence-in-cancer-patients-during-the-first-wave-of-covid 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-multicenter-randomized-phase-iii-study-for-recurrent-glioblastoma-comparing-bevacizumab-alone-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/knowledge-practice-and-attitude-on-human-papillomavirus-and-cervical-cancer-among-medical-students 2026-08-24 monthly 0.7 https://rjrindex.com/articles/vault-proteins-as-prognostic-biomarkers-and-therapeutic-targets-in-lower-grade-gliomas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pathologic-response-and-safety-of-neoadjuvant-pembrolizumab-with-or-without-entinostat-in-muscle-inv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/analysis-of-genetic-mutation-profile-and-cns-pharmacokinetics-in-relapsedrefractory-primary-cns-lym 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-role-of-occupational-carcinogens-in-laryngeal-cancer-a-global-trend-analysis-1990-2021 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immunotherapy-with-and-without-radiotherapy-following-the-diagnosis-of-bone-metastasis-for-stage-4-n 2026-08-24 monthly 0.7 https://rjrindex.com/articles/oncologists-happiness-at-work-and-integrative-oncology 2026-08-24 monthly 0.7 https://rjrindex.com/articles/breaking-down-the-505b2-drug-price-paradox 2026-08-24 monthly 0.7 https://rjrindex.com/articles/therapeutic-decisions-and-outcome-of-patients-with-stage-i-testicular-germ-cell-tumor-single-centre 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-association-between-recreational-physical-activity-and-health-related-quality-of-life-among-brea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/economic-evaluation-of-work-productivity-gains-associated-with-ribociclib-rib-in-hormone-receptor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/video-based-genetic-counseling-to-reduce-physician-workload-and-enhance-consulter-understanding-a-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/examining-factors-affecting-clinical-trial-enrolment-in-the-clinical-trials-navigator-program 2026-08-24 monthly 0.7 https://rjrindex.com/articles/correlation-between-germline-mutations-in-homologous-recombination-repair-related-genes-and-clinical 2026-08-24 monthly 0.7 https://rjrindex.com/articles/stereotactic-body-radiation-therapy-sbrt-for-prostate-specific-membrane-antigen-positron-emission 2026-08-24 monthly 0.7 https://rjrindex.com/articles/leveraging-ai-to-enhance-symptom-capture-and-reduced-hospitalizations 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-paradoxical-impact-of-depression-on-mortality-length-of-stay-and-hospitalization-charges-in-pa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/acute-myeloid-leukemia-aml-post-high-dose-cytarabine-hidac-outcomes-academic-versus-collaborati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-treatment-strategies-for-synchronous-malignancies-integrating-overlapping-regimens-for-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-profiles-patient-expectations-and-outcomes-from-an-integrative-oncology-clinic-in-india-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pioneering-cancer-survivorship-care-in-latin-america-early-results-from-the-oc-sobre-viver-program 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-hierarchical-clustering-approach-to-dissect-behavioral-symptoms-in-early-stage-breast-cancer-bc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-pembrolizumab-on-geriatric-syndromes-in-older-patients-with-nsclc-a-propensity-matched-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/initial-results-from-a-phase-i-study-of-the-shp2-inhibitor-gh21-as-monotherapy-in-patients-with-adva 2026-08-24 monthly 0.7 https://rjrindex.com/articles/fear-of-cancer-recurrence-in-long-term-colorectal-cancer-survivors-a-randomized-controlled-trial-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ai-augmentation-of-multiplex-chromogenic-assays-for-use-with-colocalized-multi-specific-targets 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-and-validation-of-the-gastric-risk-immuno-progression-score-grips-in-advanced-gastric 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preliminary-efficacy-and-safety-results-of-tislelizumab-t-and-axitinib-a-combined-with-stereotac 2026-08-24 monthly 0.7 https://rjrindex.com/articles/unveiling-inequities-racial-disparities-in-macce-outcomes-among-esophageal-cancer-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-donafenib-combined-with-interventional-therapy-and-withwithout-immunotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-use-of-carboplatin-containing-chemotherapy-in-early-triple-negative-breast-cancer-tnbc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-platform-to-identify-patients-for-cancer-vaccine-trials-the-nhs-england-cancer-vaccine-launch-pad 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sex-stratified-mortality-and-disability-adjusted-life-years-dalys-due-to-gastric-cancer-among-olde 2026-08-24 monthly 0.7 https://rjrindex.com/articles/role-of-the-combination-of-3-t-whole-body-mri-and-18f-fdg-petct-in-the-management-of-multiple-myelo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/biomarkers-of-neoadjuvant-dalpiciclib-in-patients-with-operable-her2-negative-luminal-b-breast-cance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-environmental-genetic-and-genomic-profile-of-patients-with-rapid-progression-to-metastat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-among-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc-rece 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparable-efficacy-of-venetoclax-50mg-with-posaconazole-versus-venetoclax-400mg-in-newly-diagnosed 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-disparities-in-time-to-treatment-a-comprehensive-multidisciplinary-clinic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-factors-for-survival-in-advanced-epithelial-ovarian-cancer-a-retrospective-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effect-of-chatbot-utilization-on-genetic-testing-uptake-in-diverse-clinic-settings 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inpatient-outcomes-of-breast-cancer-hospitalizations-in-the-northeastern-vs-western-united-states 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-obesity-on-immune-related-adverse-events-in-patients-with-diagnosis-of-triple-negative-bre 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hbv-tcr-t-cell-therapy-preclinical-and-clinical-insights-into-specificity-safety-and-efficacy-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/risk-factors-and-clinicopathological-features-of-young-women-with-breast-cancer-an-observational-st 2026-08-24 monthly 0.7 https://rjrindex.com/articles/incidence-predictors-and-outcomes-of-venous-thromboembolism-in-patients-hospitalized-with-thyroid 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-efficacy-of-diagnostic-imaging-for-superficial-soft-tissue-masses-on-a-community-level 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outpatient-palliative-care-consultation-and-end-of-life-outcomes-among-a-retrospective-cohort-of-pat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-with-kras-g12c-inhibitors-in-metastatic-colorectal-cancer-a-systematic-review-and-meta-ana 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-trial-of-dual-egfr-inhibition-with-cetuximab-and-afatinib-in-patients-with-recurrentmetasta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/facilitating-meaningful-patient-involvement-in-the-design-and-conduct-of-cancer-research-the-breast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tarlatamab-induced-immune-related-adverse-events-retrospective-real-world-pharmacovigilance-study-u 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clonal-hematopoiesis-ch-in-participants-with-metastatic-castration-resistant-prostate-cancer-mcrp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-1-results-of-oncobax-ak-in-combination-with-ipilimumabnivolumab-in-advanced-clear-cell-renal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-or502-an-antibody-targeting-leukocyte-immunoglobulin-like-receptor-b2-lilrb 2026-08-24 monthly 0.7 https://rjrindex.com/articles/upfront-modified-folfoxiri-plus-panitumumab-pan-versus-folfoxpan-for-unresectable-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ways-to-accelerate-the-local-implementation-and-adoption-of-the-homologous-recombination-deficiency 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-anti-vegf-amp-anti-egfrs-in-microsatellite-instable-msi-h-metastatic-colorectal-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-approaches-to-early-detection-of-colon-adenocarcinoma-evaluating-conventional-and-biomarke 2026-08-24 monthly 0.7 https://rjrindex.com/articles/scrum-japan-monstar-screen-3-comprehensive-tumor-microenvironment-analysis-via-multi-omics-in-a-lar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/detection-of-kmt2a-partial-tandem-duplication-ptd-in-aml-by-whole-genome-sequencing-wgs-address 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-survival-outcomes-of-patients-with-de-novo-stage-iv-melanoma-a-13-year-single-center-exp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-the-tolerability-and-safety-of-hedgehog-inhibitors-in-real-life-a-cohort-of-330-patie 2026-08-24 monthly 0.7 https://rjrindex.com/articles/epidemiologic-factors-and-survival-outcomes-of-patients-with-metastatic-malignant-melanoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/performance-evaluation-of-a-reflex-blood-based-methylated-ctdna-multi-cancer-early-detection-test-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/integrating-early-palliative-care-in-advanced-sarcoma-patients-for-enhanced-quality-of-life-the-sar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ultrasensitive-circulating-tumor-dna-ctdna-detection-for-prognostication-in-triple-negative-breast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pathologic-response-to-neoadjuvant-sequenced-lymphatic-sparing-sbrt-plus-pembrolizumab-in-hpv-negat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/explaining-the-relationships-between-age-endocrine-therapy-persistence-and-risk-of-recurrence-in-h 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-multicenter-study-of-frontline-maintenance-therapy-with-lifileucel-plus-pembrolizumab-in-ad 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hepatotoxic-adverse-events-with-immune-checkpoint-inhibitors-real-world-pharmacovigilance-study-usi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/jskn003-a-biparatopic-her2-targeting-adc-in-heavily-pretreated-her2-positive-breast-cancer-a-pool 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-first-line-1l-nivolumab-plus-relatlimab-nivo-rela-versus-nivo-plus-ipil 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hypothesis-generative-head-to-head-study-comparing-efficacy-of-afatinib-and-osimertinib-based-on-imm 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prevalence-and-characteristics-of-kras-g12d-mutations-in-patients-with-solid-malignancies 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-khorana-score-in-advanced-egfr-mutated-nsclc-patients-receiving-first-line-osimertini 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-complementary-value-of-ctdna-and-tissue-ngs-in-lung-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-follow-up-of-treatment-free-remission-in-chronic-myeloid-leukemia-after-discontinuation-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-bti615-on-malignant-cells-expansion-and-bone-marrow-fibrosis-in-a-myelofibrosis-mice-mod 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-prognostic-impact-of-tp53-mutation-on-survival-outcomes-in-alk-fusion-positive-lung-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cadence-of-circulating-tumor-dna-ctdna-testing-for-molecular-surveillance-in-early-stage-breast-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-longitudinal-image-derived-ai-prognostication-as-a-predictor-of-overall-survival-os 2026-08-24 monthly 0.7 https://rjrindex.com/articles/electronic-patient-reported-outcomes-with-vital-sign-monitoring-versus-usual-care-during-trastuzumab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/timing-is-everything-how-gen-ai-driven-digital-platforms-influence-the-way-real-world-cancer-patien 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-and-implementation-of-a-home-bortezomib-injection-program-in-the-us-ann-arbor-va-close 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-chemotherapy-decisions-in-low-resource-settings-with-deep-learning-a-novel-approach-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-two-electroacupuncture-regimens-on-symptoms-and-brain-structures-in-breast-cancer-surv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effects-of-a-deep-learning-network-on-imaging-quality-of-low-ibi-valu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/validating-navya-earthshot-an-ai-enabled-point-of-care-solution-for-guideline-adherent-treatment-pl 2026-08-24 monthly 0.7 https://rjrindex.com/articles/socio-economic-and-geographic-survival-disparities-among-children-with-lymphoma-in-the-usa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bc3195-a-novel-adc-targeting-cadherin-3-cdh3-updated-results-of-a-first-in-human-phase-i-study-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adjuvant-therapy-after-neoadjuvant-immunotherapy-combined-with-chemotherapy-in-locally-advanced-rese 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-body-mass-index-on-the-pathological-complete-response-among-women-with-non-metastatic-brea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/glutamine-synthetase-expression-levels-as-a-prognostic-biomarker-in-fibrolamellar-hepatocellular-car 2026-08-24 monthly 0.7 https://rjrindex.com/articles/geographical-disparities-and-temporal-trends-in-the-prevalence-of-hospitalized-esophageal-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/wilms-tumor-in-morocco-epidemiology-challenges-in-management-and-the-promise-of-micrornas-as-diag 2026-08-24 monthly 0.7 https://rjrindex.com/articles/recurrence-free-survival-dynamics-following-adjuvant-chemotherapy-for-resected-non-colorectal-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effect-of-cdc2-licensing-by-ccl5-supsup-th1-cells-following-bcl9bcl9l 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adverse-effects-of-immune-checkpoint-inhibitors-in-advanced-endometrial-cancer-a-systematic-review 2026-08-24 monthly 0.7 https://rjrindex.com/articles/validation-of-protein-biomarkers-for-early-detection-of-cervical-cancer-and-squamous-intraepithelial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessing-global-trends-of-cervical-cancer-1990-2021 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-plasma-proteomics-based-model-for-predicting-response-to-neoadjuvant-chemotherapy-in-ovarian-cance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-multifactorial-analysis-of-first-author-retention-in-asco-accepted-works 2026-08-24 monthly 0.7 https://rjrindex.com/articles/kelim-index-as-predictor-of-treatment-outcome-in-ovarian-cancer-surgery 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-characteristics-treatment-and-survival-outcomes-in-small-cell-ovarian-cancer-a-populatio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/enhancing-bereavement-education-and-emotional-preparedness-a-global-survey-of-oncology-residency-pr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/increased-racial-and-ethnic-groups-representation-in-clinical-trials-in-a-demographically-diverse-po 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-insurance-coverage-on-diagnosis-and-surgical-treatment-of-gastric-malignancies-in-urban-po 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preclinical-project-optimus-dose-escalation-of-sn-38-pro-drug-pcs11t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-and-radiometabolic-correlatives-of-ddpcr-liquid-biopsy-for-braf-v600-mutated-melanoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/key-predictors-of-peritonitis-in-ovarian-cancer-hospitalizations-insights-for-early-intervention 2026-08-24 monthly 0.7 https://rjrindex.com/articles/proportion-of-positive-lymph-nodes-in-relation-to-survival-of-patients-with-epithelial-ovarian-cance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/augmenting-clinician-workflow-to-enable-delivery-of-guideline-concordant-cancer-care-with-an-llm-bas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/geospatial-disparities-in-access-to-clinical-trials-for-aids-defining-malignancies-in-the-continenta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reproducibility-of-the-correlation-between-race-and-outcomes-associated-with-treatment-of-her2-brea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racialethnic-disparities-in-neoplasm-mortality-and-the-role-of-healthcare-access-in-the-united-stat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-impact-of-digital-patient-monitoring-on-health-outcomes-and-healthcare-resource-utilization-in-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-in-cancer-incidence-in-singapore-over-the-last-two-decades 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multi-virus-specific-t-cells-to-enhance-the-activity-of-bispecific-antibodies-in-lymphoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mainstreaming-the-diagnosis-of-lynch-syndrome-ls-in-colorectal-cancer-crc-patients-the-italynch 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-additional-bcg-versus-sequential-gemcitabine-docetaxel-in-bcg-exposed-high-risk-non-mu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-chimeric-antigen-receptor-car-t-cell-therapy-brg01-targeting-the-epstein 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effect-of-early-integrated-neuropsychological-care-in-patients-with-brain-metastases-a-phase-2-rand 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prevalence-of-current-cigarette-smoking-and-relationships-with-demographic-and-psychosocial-factors 2026-08-24 monthly 0.7 https://rjrindex.com/articles/geographic-and-demographic-disparities-in-lung-cancer-prevalence-among-young-adults-a-seer-based-an 2026-08-24 monthly 0.7 https://rjrindex.com/articles/chemotherapy-versus-targeted-therapy-in-high-and-low-nrf2-lung-adenocarcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/concurrent-chemoradiotherapy-in-locally-advanced-lung-cancer-with-cisplatin-etoposide-or-carboplatin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/keap1-mutated-renal-cell-carcinoma-rcc-characterization-of-an-emerging-molecularly-defined-rcc-su 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cardiometabolic-health-in-men-with-prostate-cancer-under-active-surveillance-following-a-home-based 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-activation-of-mapk-signaling-as-a-potential-mechanism-of-acquired-resistance-to-lorlatini 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-anti-vegf-therapy-duration-on-krasnras-wt-mcrc-survival-after-anti-egfr-therapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparing-anal-cancer-characteristics-between-asian-american-and-pacific-islander-subgroups 2026-08-24 monthly 0.7 https://rjrindex.com/articles/predictive-and-prognostic-impacts-of-sclc-comprehensive-index-sci-in-extensive-stage-small-cell-lu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/colorectal-cancer-and-sepsis-mortality-among-the-elderly-analysis-from-1999-to-2020 2026-08-24 monthly 0.7 https://rjrindex.com/articles/significance-of-changes-in-serum-ldh-and-hbdh-in-predicting-the-efficacy-of-first-line-chemoimmunoth 2026-08-24 monthly 0.7 https://rjrindex.com/articles/kras-mutant-oncolytic-virus-vaccine-therapy-for-metastatic-colorectal-cancer-a-preclinical-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immunorare-sup5sup-a-national-platform-of-5-academic-phase-ii-trials 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-of-fruquintinib-in-young-and-late-elderly-chinese-patients-with-colorectal-cancer-in-real-wor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/demographic-characteristics-of-inflammatory-bowel-disease-patients-in-saudi-arabia-and-their-relatio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-observational-study-of-application-of-multi-target-fecal-fit-dna-testing-in-postoperativ 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-data-on-the-effectiveness-and-toxicity-of-cdk-46-inhibitors-combined-with-hormonal-thera 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparision-of-operative-outcomes-based-on-exposure-to-neoadjuvant-chemotherapy-in-minimally-invasiv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/msi-h-colon-cancer-can-we-utilize-a-watch-and-wait-approach 2026-08-24 monthly 0.7 https://rjrindex.com/articles/analysis-of-trends-in-race-and-gender-disparities-in-the-incidence-of-pheochromocytoma-from-2000-to 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immunological-phenotype-as-a-predictor-for-response-after-isolated-limb-perfusion-for-patients-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/introducing-a-capacity-building-model-to-improve-cancer-research-in-mena 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-relationship-between-prr11-expression-and-prognosis-in-early-erher2-low-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-of-malignant-neoplasms-of-bone-and-articular-cartilage-across-three-decades 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-characteristics-and-prognostic-factors-for-survival-in-metastatic-osteosarcoma-a-2004-2021 2026-08-24 monthly 0.7 https://rjrindex.com/articles/advancing-therapeutic-approaches-for-targeting-kras-in-cancer-treatment 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-i-trial-of-binimetinib-plus-hydroxychloroquine-inpatients-with-previously-treated-metastatic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-frailty-on-outcomes-in-elderly-pancreatic-cancer-patients-undergoing-chemotherapy-a-natio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/endotrophin-analysis-of-a-fibroinflammatory-biomarker-during-breast-cancer-therapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/plasma-metabolomic-signatures-for-predicting-pancreatic-ductal-adenocarcinoma-survival-the-clinical 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-in-racial-and-gender-diversity-among-adult-hemato-oncology-trainees-over-last-decade-and-impa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-and-molecular-features-of-early-onset-metastatic-pancreatic-cancer-and-their-impact-on-ther 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-efficacy-of-molecule-matched-treatment-on-hyperprogressive-disease-after-immunotherapy-a-retros 2026-08-24 monthly 0.7 https://rjrindex.com/articles/recent-trends-in-us-real-world-first-line-1l-treatment-patterns-for-patients-with-locally-advanced 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-of-angiotensin-converting-enzyme-inhibitors-aceis-and-angiotensin-receptor-blockers-arbs 2026-08-24 monthly 0.7 https://rjrindex.com/articles/virtual-personalized-exercise-program-for-subjects-with-lung-cancer-a-feasibility-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/raceethnicity-socioeconomic-status-and-health-system-factors-related-to-stage-of-presentation-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tumor-flare-reactions-secondary-to-t-cell-engaging-immunotherapies-a-study-from-the-french-reisamic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-rurality-on-patients-with-synchronous-colorectal-cancers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-polycythemia-vera-treatments-with-reduced-mortality-rates-among-us-veterans 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effect-of-a-daily-scrum-at-the-gastrointestinal-oncology-ward-on-length-of-stay-a-tertiary-center-e 2026-08-24 monthly 0.7 https://rjrindex.com/articles/measuring-the-success-of-genentechs-air-site-alliance-in-enrolling-diverse-patients-a-framework 2026-08-24 monthly 0.7 https://rjrindex.com/articles/low-dose-chemotherapy-and-pembrolizumab-combined-with-radiotherapy-in-the-first-line-treatment-of-ct 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-the-safety-and-efficacy-of-sintilimab-combined-with-chemotherapy-as-neoadjuvant-therap 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tislelizumab-plus-short-course-chemo-radiotherapy-for-conversion-therapy-of-unresectable-escc-late 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-randomized-phase-iii-trial-investigating-platinum-and-taxane-chemotherapy-in-metastatic-castration-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/enhancing-patient-understanding-of-pathology-reports-insights-from-a-large-database-of-patient-inqu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-of-targeted-therapy-in-patients-with-advanced-non-small-cell-lung-cancer-in-response-to-broad-ge 2026-08-24 monthly 0.7 https://rjrindex.com/articles/molecular-correlates-of-response-in-patients-with-metastatic-castration-resistant-prostate-cancer-tr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/promis-scores-of-cancer-survivors-in-the-comprehensive-outcomes-for-after-cancer-health-coach-stud 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-county-level-medical-debt-and-timely-treatment-initiation-among-individuals-newly-dia 2026-08-24 monthly 0.7 https://rjrindex.com/articles/combined-impact-of-patients-and-disease-characteristics-on-survival-outcome-in-early-hormone-recepto 2026-08-24 monthly 0.7 https://rjrindex.com/articles/knowledge-and-practice-of-geriatric-oncology-among-cancer-care-providers-in-africa-a-cross-sectiona 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-features-and-survival-outcomes-of-small-node-negative-breast-cancer-a-multicenter-retros 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trent-002-a-prospective-multicenter-randomized-controlled-phase-ii-study-to-evaluate-the-efficacy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-multi-center-retrospective-outcomes-analysis-of-patients-with-localized-synovial-sarcoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparative-efficacy-of-parp-inhibitors-in-brca-mutated-her2-negative-breast-cancer-a-systematic-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-metaplastic-breast-carcinoma-a-rare-tumor-with-unique-clinicopathological-features-and-limite 2026-08-24 monthly 0.7 https://rjrindex.com/articles/risk-assessment-and-development-of-a-machine-learning-based-prediction-model-for-survival-in-patient 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immune-landscape-in-lung-cancer-lymphocyte-subsets-as-potential-predictors-of-treatment-outcomes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-sapylin-versus-dexamethasone-atomized-inhalation-for-ccrt-induced-oral-mucosi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterization-of-leukemia-inhibitory-factor-and-its-receptor-in-lung-adenocarcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-patient-frailty-on-the-choice-of-induction-treatment-for-transplant-ineligible-tie-newly 2026-08-24 monthly 0.7 https://rjrindex.com/articles/intraintertumoral-heterogeneity-assessed-by-blood-based-next-generation-sequencing-ngs-to-predict 2026-08-24 monthly 0.7 https://rjrindex.com/articles/open-label-phase-ibii-study-of-cetuximab-cet-plus-ly3214996-with-or-without-abemaciclib-in-patien 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-itp53i-mutation-status-on-cancer-specific-survival-after-firs 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-sbrt-followed-by-evorpacept-and-pembrolizumab-in-hpv-mediated-head-and-neck-squamous-cel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-characterization-of-anal-canal-squamous-cell-carcinoma-ascc-and-outcomes-on-matched-target 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-study-to-determine-the-clinical-and-pathological-path-response-to-neoadjuvant-nivolumab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-immunotherapy-for-patients-with-resectable-stage-iiiiv-cutaneous-melanoma-a-swedish-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-12-clinical-trial-of-jin-a02-a-4th-generation-egfr-tki-in-egfr-mutated-advancedmetastatic-n 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-word-research-on-the-effect-and-safety-of-gemcitabine-combined-with-pd-1-inhibitors-and-recombi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-hospitalized-metastatic-cancers-of-the-lip-oral-cavity-and-pharynx-with-burden-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessing-the-impact-of-race-and-sex-on-oral-squamous-cell-carcinoma-clinical-presentation 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinicopathological-features-and-survival-outcomes-in-patients-with-high-microsatellite-instability 2026-08-24 monthly 0.7 https://rjrindex.com/articles/gender-and-racial-disparities-in-survival-from-head-and-neck-cancer-a-competing-events-analysis-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cd5-deleted-chimeric-antigen-receptor-cells-senza5-cart5-to-enhance-immunotherapy-against-t-cell-n 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-anlotinib-combined-with-131i-therapy-in-the-treatment-of-distant-metastatic-d 2026-08-24 monthly 0.7 https://rjrindex.com/articles/decoding-her2-dynamics-exploring-her2-expression-across-a-real-world-breast-cancer-cohort 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-trends-in-older-adults-with-anaplastic-thyroid-cancer-atc-a-seer-database-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/global-inequities-in-sarcoma-clinical-trials-a-comprehensive-analysis-over-the-last-decade 2026-08-24 monthly 0.7 https://rjrindex.com/articles/epigenetic-and-phenotypic-signatures-of-t-cell-response-to-blinatumomab-in-pediatric-relapsed-and-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/personalized-tumor-informed-circulating-tumor-dna-as-predictor-of-progression-risk-after-long-term-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-induction-targeted-therapy-tt-with-immune-checkpoint-inhibitor-ici-therapy-switch-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/radiotherapy-plus-nimotuzumab-versus-cisplatin-in-low-risk-locoregionally-advanced-nasopharyngeal-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dissecting-survival-disparities-in-philadelphia-chromosome-positive-vs-negative-b-cell-acute-lympho 2026-08-24 monthly 0.7 https://rjrindex.com/articles/equivalence-of-ina-an-ai-based-nutrition-platform-to-human-dietitians-for-counseling-patients-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-sociodemographic-factors-and-medicaid-expansion-on-postoperative-outcomes-for-glioblastoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/advancing-global-equity-in-cancer-care-comparative-environmental-impacts-of-radiotherapy-in-brazil 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-performance-status-on-outcomes-for-solid-tumor-patients-receiving-inpatient-chemotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effects-of-uchl1-on-tolerogenic-dc-maturation-and-promotion-of-mregdc-treg-crosstalk-to-nullify-anti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effect-of-raceethnicity-on-clinical-outcomes-for-metastatic-colorectal-cancer-mcrc-patients-in-ph 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessment-of-efficacy-of-lbl-024-a-novel-and-uniquely-designed-bispecific-antibody-against-pd-l1-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/vedolizumab-or-infliximab-treatment-option-in-immune-checkpoint-inhibitor-induced-colitis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/belantamab-mafodotin-plus-lenalidomidedexamethasone-in-newly-diagnosed-intermediate-fit-amp-frail 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-follow-up-of-the-phase-2-elm-2-study-odronextamab-for-patients-pts-with-relapsedrefrac 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-co-administration-of-a-vaccine-with-immune-checkpoint-inhibitors-with-survival 2026-08-24 monthly 0.7 https://rjrindex.com/articles/relativity-020-intracranial-ic-activity-of-nivolumab-relatlimab-nivo-rela-in-patients-pts 2026-08-24 monthly 0.7 https://rjrindex.com/articles/quantification-of-tumor-subregions-in-glioblastoma-multiforme-a-volumetric-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prediction-of-post-treatment-toxicities-using-the-pre-treatment-oral-microbiome-in-the-context-of-de 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-low-dose-nivolumab-in-advanced-cancers-a-retrospective-analysis-from-medical-oncology-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/income-and-location-divide-in-myeloma-outcomes-a-call-for-equitable-care 2026-08-24 monthly 0.7 https://rjrindex.com/articles/induction-cadonilimab-combined-with-chemotherapy-followed-by-chemoradiotherapy-for-locally-advanced 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cancer-patients-views-on-clinical-research-in-brazil-concerns-knowledge-and-misconceptions-a-nat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ibii-study-of-fluzoparib-in-combination-with-dalpiciclib-in-patients-with-locally-advanced-or 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hepatitis-b-virus-reactivation-in-hepatocellular-carcinoma-patients-undergoing-immune-checkpoint-inh 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-performance-of-mtap-homozygous-deletion-detection-based-on-next-generation-sequencing-technology 2026-08-24 monthly 0.7 https://rjrindex.com/articles/alliance-a092104-a-randomized-phase-23-study-of-olaparib-plus-temozolomide-versus-investigators-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preclinical-development-of-gntbm-38-a-novel-class-i-histone-deacetylase-inhibitor-while-combined-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-iii-of-oral-paclitaxel-dhp107-vs-intravenous-paclitaxel-in-her2-negative-recurrent-or-metast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-analysis-of-thromboembolism-in-savedimpede-risk-stratified-newly-diagnosed-multiple-myel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/identification-and-validation-of-arsenic-associated-genes-and-risk-model-for-predicting-lung-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cardiovascular-risks-associated-with-aromatase-inhibitors-versus-tamoxifen-in-breast-cancer-a-syste 2026-08-24 monthly 0.7 https://rjrindex.com/articles/maintenance-therapy-with-azacitidine-and-valproic-acid-after-allogeneic-stem-cell-transplant-in-pati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nivolumab-nivo-plus-ipilimumab-ipi-vs-chemotherapy-chemo-or-nivo-monotherapy-for-microsatellit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effectiveness-of-rituximab-plus-chemotherapy-in-pediatric-burkitt-lymphoma-a-systematic-review-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tumor-derived-exosomes-tdes-as-communicators-for-cancer-development-and-metastasis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sustained-mrd-negativity-in-patients-with-newly-diagnosed-multiple-myeloma-treated-with-carfilzomib 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-characteristics-of-cancer-associated-achalasia-caa-a-25-year-review-from-a-cancer-hospit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1-study-of-parp-inhibitor-niraparib-plus-hsp90-inhibitor-pimitespib-in-solid-tumors-dos 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-report-of-ror2-directed-therapy-with-a-conditionally-active-antibody-drug-conjugate-in-advance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-association-between-emotional-distress-prior-to-receiving-immune-checkpoint-inhibitors-and-overa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-tyrosine-kinase-inhibitors-and-low-dose-immunotherapy-in-metastatic-renal-cel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-time-to-relapse-ttr-and-metastasectomy-mts-on-survival-in-leiomyosarcoma-lms-a-cans 2026-08-24 monthly 0.7 https://rjrindex.com/articles/denosumab-monotherapy-versus-bisphosphonate-switching-in-breast-cancer-bone-metastases-a-real-world 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-study-of-olaparib-in-idh1-and-idh2-mutant-advanced-chondrosarcomas-and-other-solid-tumors 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-pooled-analysis-of-jskn003-a-biparatopic-anti-her2-antibody-conjugate-adc-in-patients-with-adv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-abbv-706-a-seizure-related-homolog-protein-6-sez6-targeting-antibody-drug 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mortality-and-readmission-rates-post-car-t-cell-therapy-in-relapsedrefractory-multiple-myeloma-rea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1-first-in-human-study-of-amt-676-an-anti-cdh17-antibody-drug-conjugate-in-patients-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-non-coding-rna-lncrna-snhg11-as-a-prognostic-and-predictive-biomarker-in-metastatic-colorecta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-role-of-exercise-in-modulating-immunity-and-immunotherapy-outcomes-in-cancer-a-syste 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-disparities-with-racial-age-and-sex-differences-in-myelodysplastic-syndromes-a-surveilla 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pan-tumor-application-of-trastuzumab-deruxtecan-t-dxd-monotherapy-in-her2-3-advanced-solid-tumors 2026-08-24 monthly 0.7 https://rjrindex.com/articles/invoke-a-phase-1-study-of-okn4395-a-first-in-class-ep2ep4dp1-triple-prostanoid-receptor-antagoni 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-significance-of-the-cgrp-pathway-gene-expression-in-advanced-solid-tumors-a-sub-analysis-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-definitive-radiotherapy-with-concurrent-and-adjuvant-immune-checkpoint-inhibitors-in-pat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ib-study-of-the-combination-of-regorafenib-with-conventional-chemotherapy-in-patients-with-new 2026-08-24 monthly 0.7 https://rjrindex.com/articles/anti-trop2-adc-esg401-in-a-master-protocol-clinical-trial-for-salivary-gland-cancer-based-on-molecul 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trop2-expression-in-the-gastroenteropancreatic-neuroendocrine-tumors-an-analysis-of-179-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/improved-survival-and-prognostication-in-melanoma-patients-with-brain-metastases-an-update-of-the-m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/leap-002-long-term-follow-up-lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advan 2026-08-24 monthly 0.7